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Recirculation of Innate Lymphocyte Subsets in the Skin
Abstract
The trafficking of innate-like lymphocytes, such as γδ T cells and B-1 B cells, has garnered comparatively
little attention from the immunological community relative to conventional T and B cells. However, recent
studies have shown that innate-like cell subsets are critical for immune regulation and host defense. In
this study, we use a classic ovine lymph cannulation model to describe the phenotype and function of γδ
T cells migrating through the skin. We find that γδ T cells traveling in the skin-draining afferent lymph are
IFN-γ- and/or IL-17-producing effector cells that express high levels of the skin- and inflammation-seeking
molecule E-selectin ligand. Notably, they also lack expression of CCR7, indicating that they use alternative
receptors for egress. Next, we analyze B cell subset composition, repertoire, and trafficking in the skin of
sheep in the lymphatic cannulation model. We find a heterogeneous population of B cells in the skin and
skin-draining lymph increases in inflammation that contains a subset of B-1-like B cells coexpressing IgM
and CD11b. Furthermore, we show that skin accumulation of B cells and antibody-secreting cells during
inflammation increases local antibody titers, which may augment host defense and autoimmunity. We
then extend our findings of cutaneous B-1 B cells to the mouse, analyzing both uninflamed skin and skin
with chronic inflammation from complete Freund's adjuvant, well as human tissue. We find that B-1 B
cells, unlike conventional follicular B-2 B cells, efficiently enter into the inflamed skin and differentially
express the trafficking molecule α4β1 integrin (VLA-4), which facilitates their entry. Furthermore, innate B
cells are a contributing source of cutaneous IL-10 in both IL-10-reporter mice and normal human skin.
These findings, initiated in the sheep model then followed up and supported by experiments in mice and
human tissues, demonstrate the evolutionary similarity between mammalian species. They also validate
the utilization of multiple models to allow for experimental setups not possible in all species. More
importantly, the further characterization of γδ T cells and the new description of skin B and B-1 cells
uncovers additional targets for regulating the cellular composition of a cutaneous immune response. In
summary, the data support a model in which innate-like lymphocytes are poised to migrate into barrier
sites, including the skin, where they rapidly provide requisite effector functions, such as cytokine and/or
antibody production, and fulfill an emerging role in skin immunity.
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ABSTRACT
RECIRCULATION OF INNATE LYMPHOCYTE SUBSETS IN THE SKIN
Skye A. Geherin
Gudrun Debes
The trafficking of innate-like lymphocytes, such as γδ T cells and B-1 B cells, has
garnered comparatively little attention from the immunological community relative to
conventional T and B cells. However, recent studies have shown that innate-like cell
subsets are critical for immune regulation and host defense. In this study, we use a
classic ovine lymph cannulation model to describe the phenotype and function of γδ T
cells migrating through the skin. We find that γδ T cells traveling in the skin-draining
afferent lymph are IFN-γ- and/or IL-17-producing effector cells that express high levels of
the skin- and inflammation-seeking molecule E-selectin ligand. Notably, they also lack
expression of CCR7, indicating that they use alternative receptors for egress. Next, we
analyze B cell subset composition, repertoire, and trafficking in the skin of sheep in the
lymphatic cannulation model. We find a heterogeneous population of B cells in the skin
and skin-draining lymph increases in inflammation that contains a subset of B-1-like B
cells coexpressing IgM and CD11b. Furthermore, we show that skin accumulation of B
cells and antibody-secreting cells during inflammation increases local antibody titers,
which may augment host defense and autoimmunity. We then extend our findings of
cutaneous B-1 B cells to the mouse, analyzing both uninflamed skin and skin with
chronic inflammation from complete Freund's adjuvant, well as human tissue. We find
that B-1 B cells, unlike conventional follicular B-2 B cells, efficiently enter into the
inflamed skin and differentially express the trafficking molecule α4β1 integrin (VLA-4),
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which facilitates their entry. Furthermore, innate B cells are a contributing source of
cutaneous IL-10 in both IL-10-reporter mice and normal human skin.
These findings, initiated in the sheep model then followed up and supported by
experiments in mice and human tissues, demonstrate the evolutionary similarity between
mammalian species. They also validate the utilization of multiple models to allow for
experimental setups not possible in all species. More importantly, the further
characterization of γδ T cells and the new description of skin B and B-1 cells uncovers
additional targets for regulating the cellular composition of a cutaneous immune
response. In summary, the data support a model in which innate-like lymphocytes are
poised to migrate into barrier sites, including the skin, where they rapidly provide
requisite effector functions, such as cytokine and/or antibody production, and fulfill an
emerging role in skin immunity.
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Chapter 1: Introduction
Lymphocyte Recirculation and Trafficking
Lymphocyte recirculation is critical for immunosurveillance, host-defense and
site-specific immunity. Although it was historically observed that lymphocytes can be
found in the lymphatics (reviewed in (3)), the source of their name, it was not until the
1950s and 60s that the importance of recirculation was experimentally determined.
Gowans, using a model of rat thoracic lymph cannulation, elegantly demonstrated that if
cells were collected from the lymph, there was an eventual decline in total numbers of
cells in the thoracic duct lymph, and this could be rescued by returning the collected
cells to the animals IV (4). It was furthermore shown that lymphocytes truly recirculate
throughout the body by intravenously transferring radiolabelled cells and finding them in
the thoracic lymph (5, 6). Later studies by Bede Morris and colleagues utilized an ovine
cannulation model that allowed for cannulation of site-specific lymphatics over a greater
length of time (7-9). Organ-specific lymphocyte recirculation was first described in this
model ((10); reviewed in (11)), setting the stage for later murine studies examining
lymphocyte subsets and the molecular mechanisms of recirculation.
Two general pathways of recirculation allow lymphocytes to efficiently migrate
throughout the body: lymphocytes may arrive at peripheral lymph nodes either by
migration from the blood circulation or from tissues via the efferent lymphatics. Primarily,
blood-borne lymphocytes enter lymph nodes through high endothelial venules (HEVs)
(6). Alternatively, lymphocytes recirculate through extralymphoid tissues, such as skin or
gut, and exit these tissues by migrating into the afferent lymph to enter the draining
lymph node. Lymphocytes in lymph nodes then return to the blood stream in the efferent
1	
  
	
  

lymph via the thoracic duct (reviewed in (11)).

Figure 1. Recirculation pathways of lymphocytes from blood. Arrows indicate the
direction of flow.
Entry into either lymph nodes or extralymphoid tissues is mediated by a multistep
adhesion cascade characterized by four steps: rolling via by selectins and/or integrins;
activation of integrins via chemokine receptor signaling; activated integrins mediate firm
adhesion/arrest, and transmigration into the tissue. (Figure 2, (12-14)). Selectins are
type 1 transmembrane glycoproteins. Three selectins have been described (E-, P-, and
L-selectin), and all bind sialylated carbohydrates, require Ca+2 for binding, and have very
similar structures. Selectin specificity is conferred by slight differences in the N-terminal
2	
  
	
  

lectin domain of the protein, although there is overlap in both function and ligand (15,
16). Integrins are also type 1 transmembrane glycoproteins. These proteins form
heterodimers consisting of alpha and beta subunits. Unlike the relatively few unique
selectins, the integrin family is extensive with 18 alpha subunits and 8 beta subunits that
can form 24 different heterodimers (17). Integrins can bind a variety of extracellular
matrix proteins, such collagen and fibronectin, as well specific cellular receptors.
Although integrins are widely utilized throughout the body and in development, the most
important integrins in the immune system are the integrin pairs αMβ2 (Mac-1), αLβ2 (LFA1), α4β1 (VLA-4), α4β7 (16,	
   17). The third receptor component of the multistep adhesion
cascade is the chemokine receptor. Chemokine receptors are 7 transmembrane G
protein-coupled receptors that can be divided into four classes based on the cysteine
residue structure of a conserved region of the chemokine ligand: C, CC, CXC, and CX3C
(18). When a chemokine receptor of a cell rolling along blood vascular endothelium binds
its chemokine ligand, inside-out signaling induces a conformational change in an integrin
dimer from a low-affinity state to a high-affinity state. It is this activated integrin that can
then firmly adhere to its ligand, also expressed on the blood vascular endothelium, and
through outside-in signaling, assist in transmigration into tissues (16,	
  19). Combinations
of selectins, integrins, and chemokine receptors together form a type of “zip code” in the
body that dictates a cell’s homing capacity, or the ability to specifically migrate to and
enter a tissue. For example, T cells with L-selectin, αLβ2, and CCR7 are capable of
entering lymph nodes, whereas B and T cells expressing α4β7 and CCR9 may migrate to
the small intestines (14,	
  20). The presence or absence of trafficking molecules allows for
exquisite regulation of leukocyte homing and also presents pharmacological targets in
the treatment of tissue specific diseases.
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The zip code requirements for lymphocyte entry into the skin are best
characterized for CD4 T cells. Extensive studies have revealed that CD4 T cells can
utilize E-selectin ligand/CLA and α4β1 integrin for rolling, the chemokines receptors
CCR4, CCR8, and CCR10 for G protein coupled signaling leading to firm adhesion by
α4β1 or αLβ2 (Figure 2, (21-28) reviewed in (20, 29, 30)).

Rolling

!CLA/E-selectin!
ligand!
!α4β1!

Activation

Firm
Adhesion

Transmigration

!CCR4 – CCL17 ! ! !α4β1!
CCL22 !
!αLβ2 (LFA-1)!
!CCR10 – CCL27! !
!CCR8 – CCL1/8!
!

Figure 2. The multistep adhesion cascade highlighting the important trafficking receptors
utilized by CD4 T cells to enter the skin.
In addition to discovering what molecules mediate T cell migration into the skin, a
source of T cell programming has been identified. In human skin, previtamin D3 is
produced after exposure to sunlight in the deep epidermis, which then undergoes a slow
spontaneous isomerization to vitamin D (31). Although traditionally understood that
vitamin D was metabolized in the liver, in recent years, keratinocytes (32), macrophages
(33), and DCs (34) have been shown to break down vitamin D into it’s active metabolite,
1,25(OH)2D3, and that both forms are capable of inducing skin-homing receptors, such
as CCR10, on CD4 T cells (34). This utilization of a site-specific metabolite to program
4	
  
	
  

trafficking patterns in the skin is mirrored in the gut where retinoic acid, which is acquired
thorough the diet in the form of vitamin A, imprints both T (35) and B cells (36) with guthoming programing. However, unlike vitamin A in the gut, the role of vitamin D on B cell
trafficking is less fully understood. In vitro culture of human peripheral blood B cells with
1,25(OH)2D3 caused a downregulation of ongoing proliferation and an inhibition of
plasma cell generation (37), but how this may affect the potential of B cells to migrate to
the skin remains unknown as B cells are not currently considered a constituent of the
cutaneous immune system (29, 38, 39).

γδ T cells
Development of γδ T cell subsets
γδ T cells are innate-like T cells with unconventional (not αβ) T cell receptors that
constitute a smaller proportion of T cells than their αβ counterparts. While γδ T cells are
primarily located within the barrier surfaces of the body, such as the intraepithelium of
skin and intestine, in mice (40, 41) and ruminants (42, 43), γδ T cells are more
homogenously distributed throughout the human immune system (44, 45). Despite
differences in anatomical localization, γδ T cells across species can be divided into
functional groups based upon their development and Vδ,Vγ usage, which also often
distinguishes γδ T cells from different tissues (reviewed in (46)). This is in stark contrast
to αβ T cells that are generally subsetted by their cytokine production profiles after
antigen encounter in the periphery (47).
Murine γδ T cells develop in the thymus in functional waves with the earliest only
active during fetal development. The first fetal emigrants express Vγ5. These cells
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migrate to the epidermis and are termed dendritic epidermal T cells (DETCs) (40). The
second wave of γδ T cells are IL-17-producing γδ T cells that migrate to the skin (48-51)
and peritoneal cavity (52), and can be found in secondary lymphoid organs (51, 53). A
third wave of emigrants includes γδ NKT cells, which are abundant in the spleen and
liver (54, 55). The fourth and fifth waves, naive and γδ intestinal intraepithelial
lymphocytes (iIELs), also develop at this time, but the production of naïve and iIEL γδ T
cells continues postnatally (56, 57). Although the developmental program of human γδ T
cells is less clear, first γδ T cell subset to emerge from the thymus populates intestinal
epithelial tissues (58) and cytokine-producing γδ T cells can be found in umbilical cord
blood (59, 60).

γδ T cells in the skin
Much of the work regarding γδ T cells in the skin has focused on the function and
trafficking of murine DETCs. DETCs upregulate skin-homing receptors after TCR ligation
in the thymus (61) and, akin to skin homing CD4 T cells (20, 30), require ligands for Eand P-selectin, as well as CCR4 and CCR10 for their migration into the epidermis (62,
63). Once in the epidermis, DETCs are positioned as key regulators of cutaneous
responses. The DETC TCR is not MHC-restricted and is capable of responding to
antigens from stressed or damaged keratinocytes (64), an interaction that appears
critical for keratinocyte maintenance (65). Upon activation, DETCs are capable of
producing a variety of effector molecules including keratinocyte growth factors (KGF),
insulin-like growth factor-1, IL-2, IL-3, granulocyte-macrophage colony-stimulating factor
(GM-CSF), IFN-γ, tumor necrosis factor-α, lymphotaxin, macrophage inflammatory
protein-1α (MIP-1α), MIP-1β, and RANTES (66). Following injury by full skin thickness
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punch, macrophage recruitment is impaired in mice lacking DETCs (67). Furthermore,
wound closure is also delayed, but addition of either activated DETCs or KGF-1 restores
wound healing (68). Although classical DETCs have only been observed in mice (44, 69,
70), γδ T cells in human skin are also have restricted usage Vδ usage and recently have
been shown to produce IGF-1 in newly wounded skin (71), suggesting there are
similarities in epidermal T cells across species.
γδ T cells in the skin also participate in cutaneous immune responses, providing a
rapid, early response to viral, bacterial, and fungal infection. For example, DETCs
provide IL-17 in response to Staphylococcus aureus infection (72). Cyster and
colleagues recently observed a more abundant population of γδ T cells in skin-draining
lymph nodes compared to mucosal draining lymph nodes (48). They and others found
that a population of motile γδ T cells also resides in the dermis, and that these γδ T cells
are unique from DETCs (48, 73, 74). These γδ T cells express a different Vδ TCR, are
mostly round without dendrites, and produce large quantities of IL-17 when exposed to
IL-23 or when the skin was infected with Mycobacterium bovis (48, 73, 74). Many studies
describing DETC function employed TCRδ-deficient mice and drew conclusions on the
role of DETCs assuming that there were not appreciable numbers of γδ T cells in the
dermis. Furthermore, although the dermis and epidermis were often mechanically
separated in the isolation of epidermal γδ T cells, the possibility of dermal contamination
cannot be fully ruled out. Since we now know there is a dermal population, further
studies are necessary to delineate the functions of these two populations, especially in
inflammatory settings where dermal γδ T cells may have greater access than epidermisrestricted DETCs

7	
  
	
  

As this newly observed dermal T cell subset is capable of modulating immune
responses through IL-17 production and possibly other mechanisms, it is important to
understand how these cytokine-producing γδ T cells are mobilized to the skin. While
conventional αβ T cells depend on CCR7 to egress from extralymphoid tissues, such as
the skin, and enter afferent lymph vessels (75-77), dermal γδ T cells do not express
CCR7 (73, 78). Weninger and colleagues have demonstrated that dermal γδ T cell
numbers are normal in CCR7-knockout mice (73). A similar finding by Koets and
coworkers revealed that bovine γδ T cells exit the skin and enter in the skin-draining
lymph without expression of CCR7 (78).

Bovine skin-draining γδ T cells expressed

mRNA transcripts for CCR4 and CCR10, which as previously mentioned, can mediate
CD4 T cell entry into the skin; however, analysis of protein expression or function is
lacking. There is currently one report in a mouse model of IL-23-induced psoriasis of an
IL-17-producing γδ T cell population utilizing CCR6 to migrate from the epidermis to the
dermis (79), but blocking the ligand (CCL20) only inhibited dermis to epidermis
trafficking and did not affect accumulation in the dermis. As such, the molecules used by
recirculating γδ T cells to enter and exit the skin remain to be identified. Chapter 1 will
investigate the recirculation and functional capacity of migratory γδ T cells in the skin and
skin-draining lymph of sheep.

γδ T cells as antigen-presenting cells
In addition to effector T cell properties, one subset of human γδ T cells was
proposed to function as a professional antigen-presenting cell (APC) (80). Specifically,
upon stimulation human Vδ2+ T cells upregulated MHC class II (MHCII) and
costimulatory molecules, as well as the “tissue exit receptor” CCR7, to induce primary
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responses in naïve αβ T cells in draining lymph nodes (80). It remains unknown if this
finding also applies to γδ T cells of other species.

B-1 B cells
Development of B-1 B cells
From extensive studies in mice, B cells can be broadly divided into two lineages:
innate-like B-1 B cells and conventional, follicular B-2 B cells.1 B-1 B cells, like their
name implies, arise first in fetal development in several waves: the first wave from
precursors in the para-aortic splanchnopleura and yolk sac (82, 83), followed by
development from the fetal liver (84), and lastly from the bone marrow ((85), reviewed in
(86)). B-1 B cells are produced more abundantly in fetal and early life, and as output of
B-1 B cells decreases, the output of B-2 B cells increases. Whether this is due to the
presence unique precursors at different developmental checkpoints or is regulated by
environmental/developmental cues is not fully understood (87, 88). B-1 B cells are
CD19+, CD1dmid, CD23−, CD43+, IgDlow, IgMhi and can be divided into at least two
phenotypic subsets: B-1a and B-1b B cells, with the former also expressing CD5. Both
subsets are found primarily in the peritoneal and pleural cavities, to a smaller extent in
the spleen, as well as in significantly lower numbers in the circulation and peripheral
lymph nodes (81, 89). Although some differences in the developmental requirements
(90) and BCR specificity for B-1a and B-1b B cells (91, 92) have been described, these
subsets are phenotypically similar and self-renewing (93).
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
1
B-2 B cells also include an innate-like subset called marginal zone (MZ) B cells;
however, the B-2 designation is often restricted to just follicular B-2 B cells 81.
Baumgarth, N. 2011. The double life of a B-1 cell: self-reactivity selects for
protective effector functions. Nat Rev Immunol 11: 34-46..
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Functions of B-1 B cells
A hallmark function of B-1 B cells is the ability to secrete natural antibody (94).
Natural antibody tends to bind both pathogen structures as well as endogenous antigens
(95).

There is some dispute as to whether peritoneal B-1 B cells are capable of

secreting antibody in the peritoneal cavity without stimulation (96, 97) or whether an
activation signal is required for their exit from the peritoneal cavity and subsequent
antibody production in the spleen or bone marrow (98, 99). Despite debate on the cues
and localization required for B-1 antibody secretion, it is widely accepted that this subset
is ultimately responsible for most circulating IgM (100) as well as intestinal IgA (101,
102). B-1 B cell derived natural antibody, along with recently reported B-1-derived
antigen-specific antibody (103), is critical for effective immune responses against
pathogens and in inflammation. For example, B-1 derived IgM improved survival in
influenza infection, even in the presence of B-2-derived IgM (104), and in Borrellia
hermsii infection, B-1 IgM was sufficient to clear the bacteria (91). B-1 IgM is also critical
in the development of contact hypersensitivity, although a more recent study questions if
this IgM is perhaps produced by a unique subset of B-1 B cells (105, 106). However, the
contribution of B-1 derived antibody in many infectious and/or inflammatory settings
remains unclear.
B-1 derived IgM is also critical for tissue homeostasis by binding antigens
expressed on apoptotic cells (107, 108) and facilitating uptake by phagocytic cells (109).
Mice that are deficient in secreted IgM develop normally (110), but in a transgenic
mouse model of lupus, disease is accelerated in mice also lacking circulating IgM (111),
illustrating an anti-inflammatory role of secreted IgM in tissue maintenance.
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B-1 B cells can exhibit effector functions beyond antibody production, and
several phenotypically similar, functionally distinct populations of B-1 B cells have been
characterized in recent years. Although some labs have proposed that these functions
warrant the creation of additional innate B cell subsets, whether these functional groups
share developmental precursors or just surface markers with B-1 B cells is unclear.
Suyner and colleagues demonstrated that peritoneal B-1 cells are capable of
phagocytosing bacteria and presenting it to CD4 T cells (112). Whether B-1 B cells in
other anatomical locations are also phagocytic antigen-presenting cells has yet to be
experimentally determined. It has been known for over two decades that B-1a B cells
(then identified by expression of Ly-1, aka CD5) can produce IL-10 (113, 114). Recent
studies have further characterized these cells and show that B cell-derived IL-10 can
dampen T cell responses in a model of contact hypersensitivity (115) and infection with
cytomegalovirus (116). Furthermore, a subset of B-1a cells is capable of producing GMCSF, and B-cell derived GM-CSF was required for control of sepsis (117). Collectively,
these studies broaden our understanding of the innate potential of B-1 B cells; however,
if these cells carry out their functions beyond the peritoneum/spleen where they’ve thus
far described requires further investigation.

Migration of B-1 B cells
As previously mentioned, B-1 B cells can exit the peritoneal cavity, migrating to
the spleen or bone marrow to secrete antibody (98, 99). Furthermore, when peritoneal
B-1 B cells receive LPS or a TLR4 ligand, they rapidly exit the peritoneal cavity and
migrate to the spleen and small intestine (118-120). Furthermore, in the aforementioned
studies on the role of B-1 B cells in influenza infection and contact hypersensitivity,
peritoneal B-1s could be found in the mediastinal (92) and skin-draining lymph nodes
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(105), respectively. As B-1 B cells are capable of migration into the intestine and lung,
both barrier organs, it raises the question if B-1 cells (and B cells, in general) are
capable of migrating into another major barrier organ, the skin.
Several groups have initiated studies on the requirements of B-1 B cell
recirculation into and out of the peritoneal cavity. Cyster and coworkers conclusively
demonstrated that peritoneal B cells recirculate between the peritoneal cavity and blood
under homeostatic conditions in parabiotic mice (121). This exit is dependent on
CXCR5-CXCL13, as mice deficient in the receptor have significantly fewer B-1s in the
peritoneum (122), and B-1s in mice lacking the ligand cannot home into the peritoneal
cavity (121). Unlike peritoneal B2 or CD4 T cells, B-1 B cells do not rely on CCR7 to exit
the peritoneum (123), but instead are more dependent on S1P (124). Although
chemokine requirements for peritoneal B-1 cell entry and exit have been fairly well
characterized, the integrin requirements for B-1 cells are less clearly understood. It has
been proposed that α4 integrins could play a role in peritoneal B-1 cell homing as it is
used by B-2 B cells to enter the peritoneum (125). Furthermore, MADCAM-/-/VCAM-/double knockout mice exhibit significantly fewer B-1 B cells in the peritoneal cavity
compared to MADCAM-/- single knock-outs (125). However, whether this is because of
entry versus exit requirements or due to survival has not been investigated. Conversely,
alpha-4 integrin has been shown to play a role in peritoneal exit. After LPS stimulation,
alpha-4 and beta-1 integrins are downregulated on B-1 B cells, and this downregulation
allows for their release from the peritonium (118). Chapters 2 and 3 will investigate the
possibility of B-1 cell migration through the skin, identify a requirement for α4 integrin in
mediating entry into the skin, and propose a resolution for the dual functionality of alpha4 integrin in tissue exit and entry.
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B-1(like) cells in humans and sheep
Although B-1 B cells are best characterized in mice, innate B cells have been
described in other species, including rabbits (126), sheep (127), cattle (128), and
humans (129). In sheep, B-1-like cells are prominently found in the blood as opposed to
the peritoneal cavity, but they share many other characteristics of murine B-1s (127). In
contrast, whether the population identified as human B-1 B cells are B-1 cells at all is
hotly debated. Phenotypic overlap with circulating marginal zone B cells (130, 131) and
pre-plasmablasts (132) have lead researchers to question the ontology of the proposed
human B-1 B cells. Despite the subset controversy, B cells in the blood functionally
similar to murine B-1 B cells, such as dominant responses to B-1 antigens (133, 134),
have been described and suggest circulating innate-like B cells exist in humans.
Chapters 2 and 3 will investigate B cells in the skin and skin-draining afferent lymph or
just skin of sheep and humans, respectively, to determine if B cells and/or B-1-like cells
are present in these tissues.
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Chapter 2: Ovine skin-recirculating γδ T cells express IFN-γ and IL-17
and exit tissue independently of CCR7
Abstract
γδ T cells continuously survey extralymphoid tissues, providing key effector functions
during infection and inflammation. Despite their importance, the function and the
molecules that drive migration of skin-recirculating γδ T cells are poorly described. Here
we found that γδ T cells traveling in the skin-draining afferent lymph of sheep are
effectors that produce IFN-γ or IL-17 and express high levels of the skin- and
inflammation-seeking molecule E-selectin ligand. Consistent with a role for chemokine
receptor CCR7 in mediating T cell exit from extralymphoid tissues, conventional CD4
and CD8 T cells in skin-draining lymph were enriched in their expression of CCR7
compared to their skin-residing counterparts. In contrast, co-isolated γδ T cells in skin or
lymph lacked expression of CCR7, indicating that they use alternative receptors for
egress. Skin-draining γδ T cells were unresponsive to many cutaneous and inflammatory
chemokines, including ligands for CCR2, CCR4, CCR5, CCR8, CCR10, and CXCR3, but
showed selective chemotaxis toward the cutaneously expressed CCR6 ligand CCL20.
Moreover, IL-17+ γδ T cells were the most CCL20-responsive subset of γδ T cells. The
data suggest that γδ T cells survey the skin and sites of inflammation and infection,
entering via CCR6 and E-selectin ligand and leaving independent of the CCR7-CCL21
axis.
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Introduction
T cell recirculation through extralymphoid tissues is critical to immunosurveillance, host
defense, and inflammation. During recirculation, memory/effector T cells enter
extralymphoid organs from the blood via a multistep adhesion cascade involving
adhesion molecules and chemokines (reviewed in (135, 136)). Memory/effector T cells
subsequently exit the skin or other extralymphoid tissues by entering afferent lymph
vessels and migrating into draining lymph nodes (137). After leaving lymph nodes in the
efferent lymph, they return to the blood via the thoracic duct and continue surveying the
body.
As a barrier organ, the skin is constantly exposed to mechanical, chemical,
thermal, or vector-mediated threats and thus constantly threatened by infection following
barrier breach. The skin is also a common target of inflammation during allergy and
autoimmunity. In addition to conventional αβ T cells, γδ T cells reside in the dermis and
epidermis of mammalian skin. γδ T cells are innate-like T cells with unconventional T
cell receptors that are not major histocompatibility complex (MHC) restricted and are
hypothesized to bind a diverse set of foreign and self antigens (reviewed in (138, 139)).
Ruminants have exceptionally large numbers of these T cells, particularly early in life,
suggesting that they rely more heavily on γδ T cells for host defense relative to other
mammals (43). γδ T cells provide a rapid, early response to viral, bacterial and fungal
infection by secretion of effector cytokines such as IFN-γ, IL-4, and IL-17, and several
subsets of γδ T cells have been described based on their localization, function, and
thymic T cell receptor (TCR) – ligand interactions (reviewed in (140, 141)). For example,
dendritic epidermal T cells (DETCs), a well-studied sessile population of mouse γδ T
cells, are named for their morphology and localization. Recently, it has been shown that
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mouse epidermal γδ T cells provide IL-17 in response to Staphylococcus aureus
infection (72). However, others found that motile dermal γδ T cells, but not DETCs,
rapidly express high levels of IL-17 and are therefore critical in cutaneous infection and
inflammation in mice (48, 73, 74). Thus, it is important to understand how different
cytokine producing γδ T cells are mobilized to the skin to promote optimal host immunity
or to regulate inflammation.
DETCs upregulate skin-homing receptors after TCR ligation in the thymus (61)
and akin to skin homing CD4 T cells (20, 30), require ligands for E- and P-selectin, as
well as CCR4 and CCR10 for their migration into the epidermis (62, 63). While
conventional αβ T cells depend on CCR7 to egress from extralymphoid tissues, such as
the skin, and enter afferent lymph vessels (75-77), the molecules used by recirculating
γδ T cells to enter and exit the skin remain to be identified.
In addition to effector T cell properties, one subset of human γδ T cells was
proposed to function as a professional antigen-presenting cell (APC) (80). Specifically,
upon stimulation human Vδ2+ T cells upregulate MHC class II (MHCII) and costimulatory
molecules as well as the “tissue exit receptor” CCR7 to induce primary responses in
naïve αβ T cells in draining lymph nodes (80). It remains unknown if this finding also
applies to γδ T cells of other species.
Many studies focus on γδ T cells as they reside in the tissue or in the blood;
however, little is known about tissue-recirculating γδ T cells. Although all jawed
vertebrates have γδ T cells, the particularly large number of recirculating γδ T cells of
ruminants, including sheep and cattle (70), make them an ideal model to study migratory
γδ T cells. While ruminants and humans have epidermal and dermal γδ T cells, both
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species lack prototypic DETCs and therefore rely on a mobile surveillance of the skin by
γδ T cells (44, 69, 70). In this study, we found that ovine γδ T cells that have just left the
inflamed or uninflamed skin and are traveling in the afferent lymph, exhibit an effector
phenotype opposed to antigen-presenting capabilities. Furthermore, we show that these
cells express high levels of L-selectin and E-selectin ligand, suggesting that lymph-borne
γδ T cells are easily deployed into skin and sites of inflammation. In contrast to αβ T
cells, γδ T cells are able to exit the skin in a CCR7-independent manner. Finally, while
many γδ T cells migrate to the cutaneously expressed CCR6 ligand, CCL20, IL-17
producing γδ T cells were highly enriched in the responsive fraction, suggesting that IL17+ γδ T cells utilize CCR6 to recirculate through the skin.

Material and Methods
Animals, lymph cannulations, and induction of skin inflammation
Mixed breed intact ewes or wethers, 5–10 mo of age, were purchased from 3/D
Livestock (Woodland, CA), the University of California, Davis (Davis, CA), Animal
Biotech Industries (Danboro, PA), or Pine Ridge Dorsets (East Berlin, PA). Some blood
samples from 5-36 month old mixed breed sheep were kindly provided by Thomas
Schaer (Department of Clinical Studies-New Bolton Center). Pseudoafferent lymph
vessels were generated by surgical removal of prefemoral (subiliac) lymph nodes and
were cannulated as previously described (77, 142). Briefly, six to twelve weeks postlymphectomy, pseudoafferent lymph vessels were surgically cannulated using heparincoated catheters (Carmeda), and afferent lymph was continuously collected into sterile,
heparinized (APP Pharmaceuticals) bottles. Every 1–12h, lymph collection bottles were
changed, and lymphocytes stained for γδ T cells. A total of 0.3–0.5 ml Complete
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Freund’s Adjuvant (Sigma-Aldrich), emulsified 1:1 with sterile saline, was injected
subcutaneously into the drainage area of the prefemoral node to induce chronic (>21-d
old) inflammation, as described (77). All animal experiments were approved by the
Institutional Animal Care and Use Committee of the University of Pennsylvania.
Cell isolation
Leukocytes were isolated as previously described (2). Briefly, cells were released by
grinding lymph nodes through a cell-dissociation sieve and passed through a 40-mm cell
strainer (BD Biosciences). Cells were isolated from shaved skin by mechanical
disruption, followed by enzymatic digestion with Liberase TM and DNase I (Roche).
Subsequently, the cell suspension was filtered through a cell-dissociation sieve or a
French press coffee filter (Bodum) and washed. Blood was collected by venipuncture
and mixed with heparin. Blood leukocytes were separated from red blood cells by either
gradient centrifugation with Histopaque-1077 (Sigma-Aldrich) or lysis with red blood cell
lysing buffer (Sigma-Aldrich). Leukocytes collected from ovine lymph were washed with
RPMI (Invitrogen).
Flow cytometry
Nonspecific staining was minimized by preincubation with mouse and sheep IgG
(Jackson ImmunoResearch). After blocking, the cells were labeled with biotinylated or
fluorochrome-conjugated (FITC, PE, Alexa Fluor 647, allophycocyanin, PE-cyanin 7;
Alexa Fluor 700, Pacific Blue, Pacific Orange) monoclonal antibodies (mAbs). The
following mouse anti-sheep mAbs were used: CD4 (44.38; Serotec), CD8 (38.65;
Serotec), CD45 (1.11.32; Serotec), γδ TCR (86D (143); VMRD), MHCII molecule DR
(TH14B; VMRD), L-selectin (DU1-29; VMRD). Mouse anti-ovine CD11c hybridoma
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supernatant (17-196; (34) and mouse anti-ovine pan-B-cell marker (2-104; (2)) were
kindly provided by Alan Young (South Dakota State University). Mouse anti-human mAb
1G1 (BD Biosciences) was used to stain for CCR4. Some mouse mAbs were labeled
prior to staining using Zenon labeling kits according to the manufacturer’s instructions
(Invitrogen). B7.1/B7.2 expression was detected using a human CTLA4-Ig chimeric
protein (ID Labs). E-selectin ligand expression was assessed by testing the binding
capacity to a recombinant mouse E-selectin human IgG chimeric protein (R&D Systems)
in HBSS containing Ca2+ and Mg2+. Specificity of the binding was shown by staining in
30-50 mM EDTA buffer, which inhibits the Ca2+-dependent binding to E-selectin. CCR7
was stained using a mouse CCL19 human Fc chimeric protein (eBioscience) as
described (76). Primary incubation with either E-selectin or CCL19 chimeric protein was
followed by biotinylated F(ab)2 donkey anti-human IgG (Jackson ImmunoResearch). For
cell surface staining with biotinylated Abs, allophycocyanin- (BD Bioscience), PerCPCy5.5- (BD Biosciences), Pacific Orange- (Invitrogen), PE-cyanin 7- (eBioscience) or
Alexa Fluor 405-conjugated streptavidin (Invitrogen) was used as a secondary reagent.
When necessary, LIVE/DEAD Aqua Fixable Dead Cell Stain (Invitrogen) was used
according to the manufacturer’s instructions. Staining of digested skin was performed in
parallel with that of digested and undigested lymph node samples to verify that antigens
were not cleaved during the cell-isolation process. Intracellular staining was performed
on lymphocytes stimulated with phorbol 12-myristate 13-acetate and ionomycin (SigmaAldrich) for 4 h prior to staining as described (77). Brefeldin A (Sigma-Aldrich) was
added for the last 2 h. Surface staining for γδ TCR was followed by fixation with 2%
paraformaldehyde.

Fixed cells were then permeabilized with 0.5% saponin (Sigma-

Aldrich) and stained with the following mouse mAbs recognizing sheep antigens (77):
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anti-bovine IFN-γ (CC302; Serotec), anti-bovine IL-4 (CC303; Serotec), anti-human IL17A (eBio64DEC17; eBioscience). Samples were acquired on a BD LSRII or
FACSCalibur using FACSDiva or CellQuest software (BD Biosciences), respectively,
and analyzed with FlowJo software (Tree Star, Ashland, OR). Gates were set according
to appropriate isotype/control staining.
Chemotaxis assay
The assay was performed and analyzed as described (76, 144). Briefly, whole lymph
was collected 0-12h prior to the assay and incubated in RPMI containing 0.5% bovine
serum albumin (Invitrogen) for 1 h. 5-10 x 105 cells in 100 µl were added to 5-µm-poresized, 24-well tissue culture inserts (Corning costar). Recombinant mouse CCL2,
CCL17, CCL20, CCL21, and CXCL9 and recombinant human CCL1, CCL4, CCL20, and
CCL28 (all from R&D Systems) were titrated in triplicates, and cells were allowed to
migrate for 90 min. Leukocytes in the migrated and input wells were quantified using a
fixed number of 15 µm polystyrene beads as a standard (Polyscience Inc.) combined
with flow cytometric analysis of γδ, CD4+ and (γδ TCR–) CD8+ T cells. No difference was
noted in the efficacy of mouse or human CCL20 to attract ovine lymphocytes. To assess
the chemotaxis of cytokine producing cell subsets to CCL20 at its optimal concentration
of 10 nM (Fig. 4), we combined the analysis of total γδ T cell migration with the frequency
of cytokine-producing cells in input and migrated population (144). Specifically, a fraction
(F) of the input or migrated well was added to a fixed number of beads (B). The ratio of
cells to beads (c/b) was determined for each well by flow cytometry. Absolute number of
cells (Csample) per well =B*(c/b)/F. The remainder of each well was stimulated and
stained for T cell subsets and cytokine production as described above. To ensure
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sufficient cell numbers for intracellular cytokine staining, 6-12 wells were pooled for
staining. The percent (P) of each T cell and cytokine+ subset was determined by flow
cytometry. The migration for each subset was calculated and expressed as % of input =
100*(Csample * Psample)/(Cinput * Pinput).
Alignment of chemokine amino acid sequences
Amino acid sequences were downloaded from the National Center for Biotechnology
Information (NCBI) website and aligned using MacVector (MacVector, Inc.). Identity and
similarity were defined as identical and identical plus equivalently charged amino acids,
respectively. Percent identity and similarity of sequences shown in Table 1 were based
on the recombinant chemokines used in the chemotaxis assays and calculated using the
MacVector pair-wise analysis application.
Statistical analysis
All statistical analyses were calculated using GraphPad Prism software. Unless
otherwise indicated, all values are reported as mean ± SD, and statistical significance
was determined by student’s t test, paired when indicated. P values < 0.05 were
considered statistically significant.

Results
Skin-draining ovine γδ T cells are effectors rather than APCs.
Previously, a subset of human γδ T cells was proposed to function as an APC that
upregulates MHCII and costimulatory molecules, and by inducing expression of the
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tissue exit receptor CCR7, migrates to draining lymph nodes via the lymphatics to prime
naïve αβ T cells (80). Therefore, we addressed whether ovine γδ T cells leaving
extralymphoid tissues via afferent lymph display characteristics of professional APCs.
By using an ovine model of afferent lymph vessel cannulation (142), we were able to
examine skin-draining lymph from uninflamed and chronically inflamed skin in each
animal, which allowed for the analysis and comparison of γδ T cells in the steady state
and in the presence of chronic inflammation elicited by Complete Freund’s Adjuvant (77,
145). We stained γδ T cells draining skin for molecules that indicate the ability to present
antigen and provide costimulatory signals and compared expression levels to that of coisolated dendritic cells in the draining lymph. Expression levels of MHCII in the control
and granuloma skin-draining lymph were generally low and percentages of positive γδ T
cells were highly variable, ranging from 1.01-16.07% and 2.12-16.97%, respectively (Fig.
1A, top). While we could detect CTLA-4 binding (indicating CD80/86 expression), the
expression intensity was uniformly low (Fig. 1A, bottom). In contrast, co-isolated
dendritic cells draining the skin were uniformly MHCIIhi and expressed high levels of
CD80/CD86 (Fig. 1A).
In addition to presenting antigen, subsets of γδ T cells in humans, mice, and
cattle are capable of producing a wide variety of cytokines (146, 147). To determine
whether skin-recirculating γδ T cells were capable of producing effector cytokines, we
polyclonally stimulated lymphocytes from lymph draining uninflamed and granulomatous
skin with PMA and ionomycin and stained for intracellular cytokines. We detected
populations of IFN-γ (0.80 – 12.85%), IL-17 (0.29 – 20.76%), and IL-4 (0.059 – 2.95%)
secreting γδ T cells (one example staining is shown in Fig. 1B; Fig. 1C). Although, fewer
γδ T cells expressed IFN-γ compared to what we previously found for ovine CD4 T cells
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traveling in afferent lymph (10.5 – 39%), IL-17 expression of γδ T cells was similar to that
of CD4 T cells (2 – 6.5%) ((77), Fig. 1B and C). Thus, skin-recirculating γδ T cells appear
better suited to secrete pro-inflammatory cytokines rather than perform functions
analogous to professional APCs and are capable of contributing to host defense but
potentially also autoimmune inflammation.

Ovine γδ T cells are well equipped to recirculate through skin.
To determine whether skin-draining ovine γδ T cells are equipped with molecules that
allow for rapid recruitment into tissues, we stained them for L-selectin (CD62L) and Eselectin ligand. While E-selectin ligands mediate migration into skin and sites of
inflammation, L-selectin binds to peripheral node addressin (PNAd) and is essential to
lymphocyte homing into lymph nodes via the blood. However, in innate leukocytes, such
as neutrophils, L-selectin is central to migration into acutely inflamed tissues by binding
to heparan sulfate presented on reactive endothelial cells (148) and other ligands (149).
As expected (11, 42, 43), almost all blood- and lymph-borne γδ T cells expressed high
levels of L-selectin (Fig. 2A, C). Furthermore, blood and skin-draining γδ T cells also
expressed E-selectin ligand (Fig. 2A, B), indicating a propensity of skin draining γδ T
cells to efficiently return to the skin. However, significantly fewer γδ T cells residing in the
immunized skin expressed L-selectin when compared with γδ T cells from blood (p =
0.0002), control lymph (p = 0.0183), or granuloma lymph (p = 0.0118) (Fig. 2A, C). As
this difference in L-selectin expression was due to a physiological decrease rather than
the enzymatic cell isolation (Fig. 2D), the data suggest the existence of a less mobile,
potentially tissue-resident, population of γδ T cells in ovine skin. Our data are in line with
studies in cattle, showing that blood-borne bovine γδ T cells express E- and P-selectin
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ligand and L-selectin (150-152). Thus, ruminant γδ T cells in general exhibit a phenotype
that suggests superior capacity to enter sites of inflammation.

γδ T cells exit the skin in a CCR7-independent manner.
Mouse CD4 and CD8 T cells depend on CCR7 to exit uninflamed extralymphoid tissues
(75, 76), as its ligand, CCL21, is constitutively expressed by afferent lymphatics (153155). Consistent with a role of CCR7 as a tissue exit receptor for ovine T cells, CD4 and
CD8 T cells in the skin-draining afferent lymph express CCR7 (76). Additionally, CCR7
was suggested to mediate human γδ T cell migration from extralymphoid tissue into
afferent lymphatics (156). Thus, we addressed whether CCR7 is a potential skin exit
receptor for skin-recirculating γδ T cells. Ovine CD4 and CD8 T cells that have just left
the uninflamed or chronically inflamed skin and entered the draining lymph were
enriched in their CCR7 expression compared with their skin residing counterparts (Fig.
3A and B), suggesting that CCR7 acts as a tissue exit receptor for ovine αβ T cells.
However, only few γδ T cells expressed CCR7 in the blood, skin, or skin-draining lymph
and their chemotactic responses to the CCR7 ligand, CCL21, did not exceed basal level
responsiveness (Fig. 3A-C). From these data, we conclude that the majority of γδ T cells
must be able to egress from the skin in a CCR7-independent manner.

Lymph-borne γδ T cells are unresponsive to ligands for skin-homing and
inflammation-seeking chemokine receptors and selectively responsive to the
CCR6 ligand CCL20.
To reveal the migratory potential of skin-recirculating γδ T cells, we tested their
chemotactic responsiveness to ligands for chemokine receptors involved in αβ T cell
recruitment into skin and/or sites of inflammation (157), CCL1, CCL2, CCL4, CCL17,
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CCL20, CCL28, and CXCL9, ligands for CCR8, CCR2, CCR5, CCR4, CCR6, CCR10,
and CXCR3, respectively. Crossreactivity with ovine cells and bioactivity of the ligands
was confirmed by assessing chemotaxis of conventional CD4 and CD8 T cells in parallel
(Supplemental Figure 1A), and amino acid alignments of predicted and actual ovine
chemokines showed 62-92% similarity between ovine and the used recombinant mouse
or human chemokines (Table 1, Supplemental Figure 2). Ligands for chemokine
receptors that target human and mouse T cells to the skin, such as for CCR4, CCR8,
and CCR10 also attract ovine skin-recirculating CD4+ T cells (Supplemental Figure 1A,
(2)), indicating that these pathways are highly conserved between mammalian species.
While CCR4 and CCR10 are also important in the migration of DETCs to mouse skin
(62, 63), ovine skin-recirculating γδ T cells did not respond to ligands for CCR4, CCR8,
and CCR10 (Fig. 4A). Consistent with their lack of chemotaxis to the CCR4 ligand
CCL17, skin-draining γδ T cells did not stain for surface CCR4 using a monoclonal
antibody (Supplemental Figure 1B and C). Ovine lymph-borne γδ T cells also lacked
responsiveness to many inflammatory chemokines, such as ligands for CCR2, CCR5,
and CXCR3 (Fig. 4A), receptors that are expressed by murine dermal and human
peripheral blood γδ T cells (74, 80). Of note, all of the tested chemokines were able to
attract ovine lymph-borne CD8 and/or CD4 T cells (Supplemental Figure 1A). However,
ovine skin-recirculating γδ T cells, and to a much lesser extent blood-borne γδ T cells,
were selectively responsive to CCL20 (Fig. 4A and B), the ligand for CCR6, which is
highly expressed on mouse dermal γδ T cells (48, 74). Importantly, CCL20 is
constitutively expressed in human cutaneous vasculature (158) and the regulation of
CCR6 is critical to proper epidermal localization of DETCs (159). Thus, our data suggest
that skin recirculating ovine γδ T cells rely on CCR6 rather than the prototypical skin
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homing chemokine receptors (CCR4, CCR8, and CCR10) used by αβ T cells for their
skin tropism.

IL-17 producing γδ T cells are highly responsive to the CCR6 ligand CCL20
It is well established that (αβ) Th17 cells express CCR6 (160), and CCR6 was recently
found on mouse and human IL-17 expressing cutaneous γδ T cells (48, 73, 74, 79, 159).
Having found that skin-recirculating γδ T cells express IL-17 (Fig. 1B and C) and migrate
in response to the CCR6 ligand CCL20 (Fig. 4A), we therefore aimed to test whether IL17+ γδ T cells preferentially migrate to CCL20.

To address this we combined PMA and

ionomycin stimulation and intracellular cytokine staining with a chemotaxis assay and
found that IL-17+ γδ T cells enriched in the CCL20-responsive fraction relative to input
(Fig. 4C). In a quantitative analysis, we found that IL-17+ γδ T cell were significantly more
responsive to CCL20 than were IL-17– (IFN-γ+ [p = 0.006] or IFN-γ– [p = 0.004]) γδ T cells
(Fig. 4C and D). IL-4 producing cells were too rare to reliably analyze for their
chemotaxis (Fig. 1B and C). Thus, the expression of receptors for CCL20 is conserved
between IL-17 producing cutaneous γδ T cells from different mammalian species,
suggesting a key role for CCL20 in driving IL-17-dominated γδ T cell responses in the
skin.

Discussion
γδ T cells are innate-like T lymphocytes that act as critical responders in infection and
inflammation. Recent studies show that γδ T cells are involved in the control of bacterial,
viral, and fungal infections (72, 73, 161), as well as in a murine models of autoimmunity
(162), many of which affect the skin. Thus, understanding the functional capacity and
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trafficking patterns of skin-recirculating γδ T cells can illuminate novel targets for the
treatment of both infectious and autoimmune skin diseases.
Using a sheep model of lymph cannulation, we examined γδ T cells in the skindraining lymph and skin under homeostatic and chronic inflammatory conditions. As a
subset of γδ T cells in humans activates αβ T cells (80), we evaluated MHCII and
CD80/86 expression on skin and found that compared to co-isolated and -stained
dendritic cells, γδ T cells in skin-draining afferent lymph expressed very low to negligible
levels of MHCII and costimulatory molecules (Fig. 1A). Consistent with our data, Hopkins
et al. (1993) found MHCII expression by both ovine αβ and γδ T cells without a
significant ability to stimulate other T cells with soluble antigens (163, 164). Taken
together, we conclude that unlike dendritic cells, ovine skin-draining γδ T cells lack
sufficient expression of key molecules that define professional APCs. Additional data
support that γδ T cells in afferent lymph of ruminants are not traveling to draining lymph
nodes to activate αβ T cells in the T-cell zone, because these γδ T cells rapidly pass
through the lymph node to re-enter the efferent lymph (165) and recirculate back into
skin (42, 78).
γδ T cell-derived IL-17 plays a crucial role in neutrophil accumulation at the
effector site during infections with pathogens such as Escherichia coli and S. aureus in
mice (52, 72). Moreover, IL-17 and IFN-γ produced by mouse γδ T cells are required for
the subsequent CD4 T cell accumulation at sites of mycobacterial infection and infection
with herpes simplex virus, respectively (73, 166, 167). When evaluating the capacity of
skin recirculating γδ T cells to produce pro-inflammatory cytokines, we found that PMA
and ionomycin stimulated γδ T cells in the skin-draining lymph produced IFN-γ and IL-17
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(Fig 1B-C). Consequently, the population of cytokine-positive, skin-recirculating γδ T
cells described here is likely important in the mobile surveillance of the skin to combat
infection with pathogens that require rapid, localized responses. Additionally, cytokine
production by mouse γδ T cells is often transient and αβ T cells that respond at later time
points in the infection often produce the same cytokine signature as early γδ T cell
responders (161, 166-168). On the other hand, cytokine production by γδ T cells is
detrimental if not tightly regulated. For example, mice infected with Aspergillus fumigatus
succumb to immunopathology if IL-17 production by γδ T cells is dysregulated (161).
Therefore, proper control of γδ T cell function and localization, including the regulation of
their migration, is imperative for protective immune responses against pathogens.
As not only function but also the migratory capacity determines the full effector
potential of a T cell in an immune response, we also examined skin and skin-draining γδ
T cells for the expression of chemokine receptors involved in the exit from and entry into
the skin. Interestingly, unlike co-isolated ovine CD4 T cells, γδ T cells traveling in the skin
draining lymph were unresponsive to ligands for CCR4, CCR8, CCR10, typical skinattracting chemokines (157). Our data contrast the finding that bovine skin draining γδ T
cells express low transcripts of CCR4 and CCR10 (78). As mRNA expression does not
always correlate with functional chemokine receptor expression, it is possible that bovine
γδ T cells also lack responsiveness to CCR4 and CCR10 ligands. Alternatively but less
likely, ovine T cells could employ a different set of chemokine receptors to recirculate
through the skin as do their bovine counterparts. Unlike skin-draining CD4 and CD8 T
cells, which rely on CCR7 to exit extralymphoid tissues (75, 76), ovine γδ T cells in the
skin and skin-draining lymph lacked surface expression of CCR7 and responsiveness to
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the CCR7 ligand CCL21 (Fig. 3). These findings are in line with a recent study, showing
that bovine γδ T cells in the skin-draining afferent lymph lack CCR7 (78) and with
findings in the mouse that exclude a role for CCR7 in dermal γδ T cell homeostasis (73).
Interestingly, during the chronic phase of inflammation, mouse αβ T cells can also exit
the skin independently of CCR7 (77). It is possible that alternative skin exit receptors
used by γδ T cells are shared with other leukocytes, such as CD4 and CD8 T cells during
chronic inflammatory conditions. Thus, targeting exit receptors could be a novel
approach to manipulate accumulation of γδ T cells, and potentially other leukocytes,
thereby modulating tissue inflammation and host responses to infection. Surprisingly,
ovine skin-recirculating but not blood-borne γδ T cells were selectively responsive to the
CCR6 ligand CCL20 (Fig. 4A-B). Not only is CCL20 upregulated in the inflamed
epidermis and other sites of inflammation, CCL20 is also constitutively expressed in
human cutaneous lymphatic and blood vasculature (158, 169), and CCR6 has been
implicated in human Langerhans cell precursor migration to the skin (158). Furthermore,
in a mouse model of psoriasis, a subset of γδ T cells utilizes CCR6 to migrate into the
inflamed epidermis (79). Thus, a subset of γδ T cells in sheep likely also uses the CCR6CCL20 axis to enter the dermis and/or sites of inflammation, to migrate from the dermis
to the inflamed epidermis, or to egress from the dermis through the afferent lymph.
Our finding that ovine skin-recirculating γδ T cells with the capacity to make IL-17
upon stimulation were enriched in their CCL20 responsiveness relative to other lymphborne γδ T cell subsets (IFNγ+ or IL-17–, or IFNγ– γδ T cells) is consistent with recent
data in the mouse showing that dermal γδ T cells are poised to make IL-17 and express
CCR6 (48, 73, 74). Thus, the link of IL-17 production by cutaneous γδ T cells and
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expression of CCR6 is evolutionarily conserved. It is tempting to speculate that ovine
skin-recirculating γδ T cells are homologous to the IL-17+ dermal γδ T cells in the mouse.
Dermal γδ T cells of mice and skin-recirculating ovine γδ T cells not only share the ability
to produce IL-17 and express CCR6, they also both express variant TCRs (73, 170,
171). Similarly, data suggest that mouse dermal γδ T cell can recirculate because they
also localize to the skin-draining lymph node in the subcapsular sinus (48), where
afferent lymph enters the lymph node. However, the potential for murine dermal γδ T
cells to recirculate has yet to be assessed.
In cattle, γδ T cells express the transmembrane glycoprotein WC1, the isoform of
which marks distinct functional subsets of γδ T cells (172). For example, IFNγ and IL-10
production by bovine γδ T cells are associated with specific WC1 isoform usage (172,
173). Most γδ T cells in adult sheep also express this molecule (also known as T19;
(143)), and although ovine isoforms are less well-characterized (174), it would be
interesting to investigate WC1 expression by IL17+ γδ T cells.
As previously mentioned, TCR diversity differs between skin-resident DETCs and
motile dermal γδ T cells. DETCs have restricted TCR usage, while dermal γδ T cells
exhibit significantly more diverse TCRs, enabling them to respond to a greater repertoire
of unique antigens than their sessile counterparts (72, 73, 170, 171). The ability to
divide the workload of continuous immunosurveillance between resident and
recirculating subsets of γδ T cells would be advantageous to achieving consistent and
robust protection from exogenous threats.

While resident γδ T cells would be

guaranteed to be near the site of barrier breach, cell number limitations and receptor
diversity could restrict their ability to combat infection.
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Accordingly, reinforcing the

protection provided by resident cells with a highly mobile, receptor-diverse population
that can also rapidly respond would permit the robust response required for barrier
surfaces, such as the skin, that are under constant microbial attack.
In conclusion, we show that migratory γδ T cells capable of producing IL-17 and
IFN-γ constantly provide immunosurveillance of the skin. They egress from the skin in a
CCR7-independent manner, and potentially use CCR6 and E-selectin ligand for efficient
cutaneous recirculation. Together, these properties make γδ T cells ideal first responders
to cutaneous infection, bridging the gap between innate and adaptive immunity.
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Chemokine
Fragment
CCL1
CCL2

Speciesutilized
fragment

H. sapiens24-96
M. musculus
H. sapiens
M. musculus2496

CCL4
CCL17

H. sapiens24-92
M. musculus
H. sapiens
M. musculus2493

CCL20

H. sapiens27-96
M. musculus2796

CCL21

H. sapiens
M. musculus24133

CCL28
CXCL9

H. sapiens23-127
M. musculus
H. sapiens
M. musculus22126

NCBI
Accession
Number
EAW80204.1
AAI20807.1
EAW80212.1

Identity
(%)
41
33
67

Similarity
(%)
62
54
84

AAH55070.1
AAI04228.1
AAI19258.1
AAI12069.1

50
84
82
51

69
92
90
66

EAW70878.1
AAH28504.1

47
67

67
84

AAH27918.1
AAH27918.1

58
73

79
86

NP_035254.1
ABB13417.1
AAH55864.1
AAH95396.1

69
78
59
72

80
90
76
81

AAH03343.1

61

73

Predicted Ovis
aries Accession
Number
XP_004013255.1
XP_004012520.1
XP_004012496.1
XP_004015612.1

XP_004005034.1

XP_004004168.1
ABB13417.1*
XP_004004168.1

Table 1. Cross-species comparison of amino acid sequences between used
recombinant and Ovis aries chemokines. Amino acid sequences for chemokines of
each species (H. sapiens, M. musculus and O. aries) corresponding to the amino acid
sequence of the used recombinant proteins were aligned and analyzed. Identity is
defined as identical amino acids, and similarity includes identical as well as amino acids
with similar charge. The species (H. sapiens or M. musculus) from which the
recombinant protein was derived is bolded. *actual sequence
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Figure 1. Skin-draining γδ T cells are effectors rather than APCs. Leukocytes from
uninflamed (control) and chronically inflamed (granuloma) skin-draining lymph were analyzed.
+

hi

–

(A) Flow cytometric analysis of γδ T cells and dendritic cells (MHCII , CDllc , pan-B ) for the
expression of MHCII and CD80/86. One representative animal of 2 (control) or 3 (granuloma)
individually analyzed animals is shown. Shaded histograms indicate isotype control staining. (BC) Flow cytometric analysis of IFN-γ, IL-17, and IL-4 expression on gated PMA and ionomycin
stimulated γδ T cells from skin granuloma draining lymph for one representative animal. (C)
Percentage of cytokine-positive γδ T cells after PMA and ionomycin stimulation for uninflamed
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(control, filled symbols) and chronically inflamed (granuloma, open symbols) skin-draining lymph
from all animals analyzed (N=9 sheep). Each symbol represents an individually analyzed sheep.
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Figure 2. L-selectin and E-selectin ligand expression by γδ T cells. γδ T cells from blood,
control and chronically inflamed (granuloma) skin-draining lymph, and granulomatous skin were
analyzed. (A) Flow cytometric analysis of L-selectin and E-selectin ligand on gated γδ T cells.
One representative animal is shown. Staining control for control lymph is shown and is
representative of all tissues. (B and C) Percentage of γδ T cells expressing E-selectin ligand (B)
or L-selectin (C) for each tissue from all animals analyzed (N=3-8). Each individually analyzed
sheep is represented by a unique symbol. (D) L-selectin expression levels by γδ T cells after
mechanical or enzymatic (digest) isolation from lymph nodes.*p < 0.05.
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Figure 3. γδ T cells exit the skin independently of CCR7. T cell subsets from uninflamed and
granulomatous skin and skin-draining lymph, as well as blood, were analyzed. (A-B) Flow
cytometric analysis of gated CD4, CD8, and γδ T cells for expression of CCR7. One example
staining with isotype controls shown as shaded areas (A), or means of 7-10 (lymph) or 3-5 (skin)
individually analyzed sheep (B) are depicted. (C) Chemotaxis of lymph-borne γδ, CD4 and CD8 T
cells to CCL21 in an ex-vivo Transwell chemotaxis assay. Data are expressed as the percentage
of cells of each T cell subset that migrated to the lower chamber, and data represent the mean ±

36	
  
	
  

SD of triplicate wells at each concentration. One representative animal of at least 4 animals
analyzed for each condition is shown. ***p<0.005; **p<0.01.
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Figure 4. Chemotactic responses of lymph- and blood-borne γδ T cells. (A) Chemotaxis of
lymph-borne γδ T cells draining uninflamed (Control) or chronically inflamed skin (Granuloma)
and (B) blood-borne γδ T cells to human (h) CCL1, CCL4, CCL20 and CCL28 and mouse (m)
CCL2, CCL17, CCL20, and CXCL9 was tested in an ex-vivo Transwell chemotaxis assay. One
representative chemotaxis profile for 2 (CCL2 and CCL4, control lymph) or 3-6 individually
analyzed sheep is shown. (C and D) Chemotaxis of γδ T cells from granulomatous skin-draining
lymph to 10nM CCL20 was assessed by gating on γδ T cells by flow cytometry. One out of two
experiments with similar results is shown. (C) IL-17 and IFN-γ expression by γδ T cells of the input
population and of γδ T cells that migrated to CCL20 or media alone. (D) Chemotaxis
+

+

quantification of γδ T cell subsets (IFN-γ and IL-17 as well as IFN-γ/IL-17 double-negative (nonproducers)) in response to CCL20 or media. (A, B, and D) Data are expressed as the percentage
of input cells of the respective subset that migrated to the lower chamber, and represent the
mean ± SD of triplicate wells at each concentration. (C and D) Cytokine production was assessed
after migration by PMA and ionomycin stimulation.**p<0.01.
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Supplemental Figure 1. Chemotactic responses of lymph-borne CD4 and CD8 T cells. (A)
Chemotaxis of uninflamed skin draining CD4 and CD8 T cells to human (h) CCL1, CCL4, CCL20
and CCL28 and mouse (m) CCL2, CCL17, CCL20, and CXCL9 was tested in an ex-vivo
Transwell chemotaxis assay. The response profile for CD4 and CD8 T cells was assessed in
parallel to that of γδ T cells of the same animal shown in Figure 4A (left), and is representative of
3-6 individually analyzed sheep for each chemokine and cell subset. Data are expressed as the
percentage of cells of the respective subset that migrated to the lower chamber, and represent
the mean ± SD of triplicate wells at each concentration. Horizontal lines indicate migration to
media alone. Similar CD4 T cell responses to CCL1, CCL17, CCL20, and CCL28 were previously
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published in (2). (B) Surface expression of CCR4 on gated CD4 and γδ T cells from control skindraining lymph of all animals analyzed (N=8) is shown. (C) One example staining of CD4 and γδ T
cells from (B). Gates represent percent positive.
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Supplemental Figure 2. Chemokine amino acid sequences are similar between mammalian
species. Amino acid sequences for recombinant chemokines used in this study and the full
length sequences for sheep (Ovis aries), mouse (Mus musculus), and human (Homo sapiens),
obtained from NCBI, were aligned. Identical and similar amino acids are marked in blue and
yellow, respectively.
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CHAPTER 3: The skin, a novel niche for recirculating B cells
Abstract
B cells infiltrate the skin in many chronic inflammatory diseases caused by autoimmunity
or infection. Despite potential contribution to disease, skin-associated B cells remain
poorly characterized. Using an ovine model of granulomatous skin inflammation, we
demonstrate that B cells increase in the skin and skin-draining afferent lymph during
inflammation. Surprisingly, skin B cells are a heterogeneous population that is distinct
from lymph node B cells, with more large lymphocytes as well as B-1-like B cells that coexpress high levels IgM and CD11b. Skin B cells have increased MHCII, CD1, and
CD80/86 expression compared with lymph node B cells, suggesting that they are wellsuited for T cell activation at the site of inflammation. Furthermore, we show that skin
accumulation of B cells and antibody-secreting cells during inflammation increases local
antibody titers, which could augment host defense and autoimmunity. While skin B cells
express typical skin homing receptors such as E-selectin ligand and alpha-4 and beta-1
integrins, they are unresponsive to ligands for chemokine receptors associated with T
cell homing into skin. Instead, skin B cells migrate toward the cutaneously expressed
CCR6 ligand CCL20. Our data support a model in which B cells use CCR6-CCL20 to
recirculate through the skin, fulfilling a novel role in skin immunity and inflammation.
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Introduction
The skin is a barrier organ that protects the body from external threats and thus harbors
many resident leukocytes, including macrophages, dendritic cells, and T cells. During
inflammation, these and additional leukocyte subsets are recruited into the skin (175).
Although B cells are found in the afferent lymph draining uninflamed skin of both sheep
and humans (176, 177), the widely accepted view is that B cells do not enter the skin
during homeostasis (178). In contrast, B cells accumulate in the dermis during infection
and autoimmunity (179-181), and B cell malignancies can manifest as cutaneous
lymphomas. However, despite their association with a wide array of skin pathologies,
the phenotypic and functional attributes of skin B cells remain unknown.
B cells can be divided into two lineages, B-1 and B-2 B cells. B-2 B cells include
the conventional mature B cell subsets, marginal zone and follicular B cells. B-1 B cells,
on the other hand, are an innate-like subset that resides in the peritoneal and pleural
cavities and responds to T-independent antigens, bridging innate and adaptive immune
responses (81, 182). Although their primary residence is within the coelomic cavities, B1 B cells are capable of exiting the body cavities in response to infection (92, 183);
however, they have not been described to enter the skin.
Lymphocyte recirculation is required for immunosurveillance, host defense and
site-specific immunity.

There are two general pathways of lymphocyte recirculation:

lymphocytes may arrive at lymph nodes from either blood or extralymphoid tissues
(reviewed in (11)). Primarily, blood-borne lymphocytes enter lymph nodes through high
endothelial venules. Alternatively, lymphocytes recirculate through extralymphoid
tissues, such as skin, and exit these tissues by migrating into the afferent lymph to enter
the draining lymph node, and then return to the blood stream in the efferent lymph via
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the thoracic duct. While two distinct blood-borne B cell subsets differentially recirculate
through lymph node or spleen (184) and IgA+ B cells preferentially recirculate through
mucosal sites (185), little is known about B cell recirculation through non-mucosal
extralymphoid tissues. To home to the skin, CD4 T cells rely on the coordinated
expression of E-selectin and alpha-4 beta-1 integrin and utilize the chemokine receptors
CCR4, CCR8, and/or CCR10 (reviewed in (20, 29, 30)). In contrast, the molecules
involved in B cell migration to the skin remain uncharacterized.
In order to investigate B cells in the skin, we have employed a model of lymph
cannulation (9) and show that B cells not only traffic through, but are also present in both
uninflamed and chronically inflamed skin. We demonstrate that skin B cells are a
heterogeneous population consisting of small and large lymphocytes with a subset
exhibiting a B-1-like phenotype. In addition, skin B cells are well equipped for antigen
presentation to T cells in situ and antibody-secreting cells, the effector stage of B cells,
accumulate in the chronically inflamed skin leading to increased local antibody titers.
While skin B cells express alpha-4 and beta-1 integrins and E-selectin ligands, unlike
skin T cells, they do not respond to ligands for chemokine receptors associated with T
cell homing into skin. Instead, skin B cells are responsive to the cutaneously expressed
CCR6 ligand CCL20. These data suggest that skin B cells are key to cutaneous
immunity and inflammation and that they utilize CCR6 - CCL20 to home to the skin.
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Materials and Methods
Animals, lymph cannulation, and induction of skin inflammation
Intact female or wethers of mixed breed sheep, 5-10 months of age, were purchased
from 3/D Livestock (Woodland, CA), the University of California, Davis (Davis, CA),
Animal Biotech Industries (Danboro, PA), or Pine Ridge Dorsets (East Berlin, PA).
Prefemoral (subiliac) lymph nodes were surgically removed to generate pseudoafferent
lymph vessels as previously described (142). Briefly, following lymphectomy, the afferent
and efferent lymph vessels anastomose, forming pseudoafferent vessels that carry
afferent (prenodal) lymph (142). 6 –12 weeks post lymphectomy, pseudoafferent lymph
vessels were surgically cannulated using heparin-coated catheters (Carmeda) and
afferent

lymph

was

continuously

collected

into

sterile,

heparinized

(APP

Pharmaceuticals) bottles. The cannulated lymphatics drained the skin and muscles of
the rear flank (186). Every 1–12 hours, lymph collection bottles were changed, and the
composition and numbers of lymph-borne leukocytes was determined by flow cytometry
to calculate the hourly output of different lymphocyte subsets (B cells, CD4, CD8, and γδ
T cells). A total of 0.3 – 0.5 ml Complete Freund’s Adjuvant (CFA) emulsified 1:1 with
sterile saline was injected subcutaneously into the drainage area of the prefemoral node
to induce acute (less than 24h) or chronic (greater than 21 days) inflammation as
described (77). Mesenteric efferent lymph vessels were cannulated as described (145)
either in parallel to cutaneous afferent lymph vessel cannulation or as an independent
non-survival surgery. All animal experiments were approved by the Institutional Animal
Care and Use Committee of the University of Pennsylvania.
Cell isolation
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Cells were released by grinding lymph nodes through a cell dissociation sieve with size
40-60 mesh (Sigma Aldrich) followed by passage through a 40 µm cell strainer (BD
Biosciences). Cells were isolated from shaved skin by mechanical disruption followed by
three 20-min enzymatic digestion steps using 0.1 mg/ml DNase I (Roche Diagnostics)
and 0.13 U/ml Liberase TM (Roche Diagnostics) in HBSS at 37°C. Between digestion
steps, released cells were collected and washed with assay media [RPMI 1640 medium
(Invitrogen) with 5% newborn calf serum (Hyclone Laboratories)]. Subsequently, the cell
suspension was filtered through a cell dissociation sieve with size 40-60 mesh (Sigma
Aldrich) or French press coffee filter (Bodum) and washed. Blood was collected by
venipuncture and mixed with heparin. Blood leukocytes were separated from red blood
cells by either gradient centrifugation with Histopaque-1077 (Sigma Aldrich) or lysis with
red blood cell lysis buffer (Sigma Aldrich). Lymphocytes collected from ovine lymph
were washed with assay media.
Flow cytometry
To reduce nonspecific staining, cells were preincubated with mouse and sheep IgG
(Jackson ImmunoResearch). After blocking, the cells were labeled with biotinylated or
fluorochrome-conjugated (fluorescein isothiocyanate, phycoerythrin, Alexa Fluor 647,
allophycocyanin, phycoerythrin-cyanine 7; Alexa Fluor 700, Pacific Blue) monoclonal
antibodies. The following mouse anti-sheep antibodies were used: CD1 (20.27; Serotec),
CD4 (44.38; Serotec), CD8 (38.65; Serotec), CD45 (1.11.32, Serotec,), γδ TCR (86D;
VMRD), MHCII (TH14B; VMRD), L-selectin (DU1-29; VMRD), IgM (25.69; Serotec). The
following mouse anti-human monoclonal antibodies that also recognize sheep integrins
(22, 187) were used:

alpha-4 integrin (HP2/1, Serotec), beta-1 integrin (TS2/16;

Ebioscience), and beta-7 integrin (fib27; Ebioscience). Supernatants for the following
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ovine antigens were produced from hybridomas: pan-B cell marker (2-104) (184, 188),
CD21 (2-87-6) (165, 189), CD11b (12-5-4) (190), and CD11c (17-196) (20). Some
mouse monoclonal antibodies were directly labeled prior to staining using Zenon labeling
kits according to the manufacturer’s instructions (Invitrogen). B7.1/B7.2 expression was
detected by CTLA4-Ig binding (human chimeric protein; ID Labs). E-selectin ligand
expression was tested by assessing binding capacity to a recombinant mouse E-selectin
human IgG chimeric protein (R&D Systems) in HBSS containing Ca2+ and Mg2+, followed
by biotinylated F(ab’)2 donkey anti-human IgG (Jackson ImmunoResearch). Specificity
of the binding was shown by staining in 30 mM EDTA buffer, which inhibits the Ca2+dependent

binding.

For

cell

surface

staining

with

biotinylated

antibodies,

allophycocyanin- (BD Bioscience), Peridinin Chlorophyll Protein-Cy5.5 (BD Biosciences),
Pacific Orange (Invitrogen) or Alexa Fluor 405-conjugated streptavidin (Invitrogen) were
used as secondary reagents. When necessary, LIVE/DEAD Aqua Fixable Dead Cell
Stain (Invitrogen) was used according to manufacturer’s instructions. Staining of
digested skin was performed in parallel with that of digested and undigested lymph node
to verify that antigens were not cleaved during the cell isolation process. Samples were
acquired on a BD LSRII or FACSCalibur using FACSDiva or CellQuest software (BD
Biosciences), respectively, and analyzed with FlowJo software (Tree Star, Ashland, OR).
Gates were set according to appropriate isotype control staining.
Histology and cytology
Concurrently, skin samples were frozen in OCT (Sakura Finetek), and 6-µm sections
were fixed in acetone (Fisher Scientific). For immunofluorescence, sections were
rehydrated for 5-10 min at room temperature with 100mM Tris-HCL (TEKnova) and
blocked with immunofluorescence buffer: 10% rat serum (Equitech-Bio) in 20 mM Tris
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with 0.9% NaCl and 0.05% Tween20 (Sigma Aldrich). Sections were incubated with antisheep IgM (25.69; Serotec), washed in IHC buffer, subsequently stained with anti-mouse
IgG1 FITC (RMG1-1, Biolegend), and embedded with Prolong Gold anti-fade
(Invitrogen).

For cytologic analysis, lymph-borne lymphocytes were subjected to

cytospins using a Shandon Cytospin 3 and subsequent Pappenheim stain (MayGrünwald and Giemsa (Sigma Aldrich) as per manufacturer instructions). For FACSsorting of lymph-borne cells prior to cytospin, a FACSVantage Diva, Aria SORP Green,
or Aria SORP was used. Fluorescence images were acquired on a Nikon Eclipse E600
microscope using a Photometrics Coolsnap EZ camera and NIS-Elements BR 3.0
software. Brightfield images were aquired using oil immersion on an Olympus BX40F4
microscope with a CC12 camera and NETCAM MicroSuite software (Olympus, Center
Valley, PA.). Cell diameters were measured using NIS-Elements BR 3.0 software, and a
minimum of 70 cells per population and animal were analyzed to determine the average
population diameter. Contrast adjustments, applied to the whole image, were performed
as needed using Adobe Photoshop.
Chemotaxis assay
The assay was performed and analyzed as described (76, 144). Recombinant mouse
CCL17 and recombinant human CCL1, CCL20, and CCL28 (R&D Systems) were titrated
in triplicates between 1 and 100 nM or 10 and 300 nM, and cells were allowed to migrate
for 90 min.
ELISA and ELISPOT assay

For ELISAs, Immulon 4 HBX 96-well plates (Nunc) were coated overnight at 4°C with 1
µg/ml rabbit anti-ovine IgG (H+L) (Invitrogen), blocked with heat-inactivated rabbit serum
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(Gibco), and washed with PBS-Tween (PBS containing 0.05% Tween-20). Sterile-filtered
blood and lymph plasma samples were diluted with PBS, added to the plate, and
incubated for 2 h at 37°C. Plates were washed with PBS-Tween and incubated for 1 h at
37°C with 0.2 µg/ml rabbit anti-ovine IgG (H+L) HRP conjugate (Invitrogen) diluted in
PBS containing 0.1% heat-inactivate rabbit serum and 0.05% Tween-20. Plates were
washed with PBS-Tween, developed for 5 min using TMB Single Solution (Invitrogen),
quenched with 1 M HCl, and read immediately at OD490 using a E Max Endpoint ELISA
microplate reader (Molecular Devices). A standard curve derived from whole ovine IgG
(Jackson Immunoresearch) on the same plate was used to quantify antibody titers.
For ELISPOT assays, MultiScreen HTS 96-well filter plates (Millipore) were
treated with 35% ethanol for 1 min and washed with PBS. To detect total Ig secreting
cells, plates were coated with 5 µg/ml rabbit anti-ovine IgG (H+L, Invitrogen) overnight at
4°C, washed with PBS, and blocked with heat-inactivate rabbit serum (Gibco). Cells
were plated in RPMI-1640 containing 10% heat-inactivated rabbit serum (Invitrogen) and
incubated for 12 to 14 h at 37°C and 5% CO2. Plates were then washed with PBSTween and incubated for 1 h at 37°C with 1 µg/ml rabbit anti-ovine IgG (H+L) HRP
conjugate (Invitrogen). Next, the plates were washed with PBS-Tween followed by PBS.
The plates were developed using an AEC Peroxidase Substrate Kit (Vector
Laboratories) as per manufacturer’s instructions, allowed to dry overnight, and the spots
were enumerated using an Olympus SZ51 dissecting microscope (Olympus). The limit
of detection was 5 ASC per 106 cells. Values below this threshold are displayed as 0.
ELISPOT wells were photographed using an ImmunoSpot Reader (Cellular Technology
Ltd.) and Image Acquisition software (Cellular Technology Ltd.).
Statistical Analysis
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All statistical analyses were calculated using Graphpad Prism software. Unless
otherwise indicated, all values are reported as mean ± SEM, and statistical significance
was determined by the nonparametric Mann Whitney U test. For paired analysis, if
indicated, the Wilcoxon test was used. P<0.05 was considered statistically significant.

Results
B cells reside in and recirculate through uninflamed skin
B cells contribute to many skin diseases, but their role in cutaneous immunity is not well
characterized. In contrast to the notion that B cells are generally absent from the
uninflamed dermis (177, 178), we consistently detected a population of B cells in the
skin of sheep (5.9 ± 1.4% of skin lymphocytes; staining of one representative animal
shown in Fig. 1A). To determine whether B cells not only reside in but also recirculate
through the skin, we employed a lymph cannulation model established by Morris and
colleagues (9). By cannulating the skin draining afferent lymphatics, the model allows for
the analysis of lymphocytes during their physiological recirculation through uninflamed
and inflamed skin (137). Due to a number of limitations, the comprehensive analysis of
lymphocyte in the skin draining afferent lymph is currently not possible in rodents or
humans. Consistent with Mackay et al. (176), we found a population of B cells in the
skin-draining lymph (9.6 ± 2.5% of lymphocytes; N=9; one representative staining shown
in Fig. 1A). When analyzing the cells traveling in afferent lymph, we found, as expected,
mainly lymphocytes, few macrophages/dendritic cells and the occasional neutrophil (Fig.
1B). Interestingly, B cells sorted from the afferent lymph were comprised of both small
and slightly larger lymphocytes (Fig. 1C). The small B cells averaged less than 10 µm in
diameter with a scant rim of basophilic cytoplasm, while larger B cells greater than 11
µm contained slightly more basophilic cytoplasm, which is cytologically suggestive of an
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activated phenotype. The results indicate that a heterogeneous population of B cells
passes through the skin and enters lymph during its physiological recirculation through
the body.

B cell traffic through the affected site increases in chronic skin inflammation
Many infectious and autoimmune diseases cause chronic skin inflammation that is
characterized by granuloma formation (191). We employed an established model of
granulomatous skin inflammation, in which inflammation is induced by subcutaneous
injection of Complete Freund’s Adjuvant (CFA) (77, 145). Draining lymph vessels were
surgically cannulated 3-4 weeks later when the typical skin granulomas had formed at
the injection sites. As previously shown for total lymphocytes and T cells (77), chronic
inflammation also boosted the absolute numbers of B cells exiting the skin (Fig. 2A).
Importantly, B cells were the only lymphocyte subsets that showed a consistent relative
increase in lymph draining chronically inflamed skin relative to uninflamed (control) skin
in all animals (P=0.0078; Fig. 2B; one example staining shown in Fig. 2C). The
percentage of all other lymph-borne lymphocyte subsets (CD4, CD8, and γδ T cells) was
not consistently elevated, unchanged, or decreased (Fig. 2B). The data demonstrate that
chronic inflammation particularly enhances B cell traffic through the skin.

B cells accumulate in chronically inflamed skin
Having found an increase in lymph-borne B cells draining chronically inflamed skin, we
isolated lymphocytes from 3-week old skin granulomas. We observed that the
percentage of B cells was significantly higher in the chronically inflamed skin compared
with uninflamed skin (38.3 ± 2.2% vs. 5.6 ± 1.1%; P=0.0079) (Fig. 3A). We also detected
B cells by immunofluorescent staining of frozen skin section in both uninflamed and
granulomatous skin (Fig. 3B – F). While only very few IgM+ B cells were visible in the
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deep dermis of the uninflamed skin (Fig. 3B and C), the dermal and subcutaneous
granuloma harbored numerous IgM+ B cells that were dispersed throughout the tissue
(Fig. 3D and E) or formed clusters in some areas of the granuloma (Fig. 3F). Thus, B
cells are a major constituent of the lymphocytic infiltrate of chronically inflamed skin,
suggesting a role for B cells in contributing to the inflammatory process.

Skin B cells express high levels of costimulatory molecules and MHCII
B cell traffic through and residence in uninflamed and inflamed skin raised the possibility
that skin B cells may participate in local immune responses by interacting with colocalizing skin T cells. To explore whether skin B cells are equipped for efficient T cell
activation, we examined antigen-presenting and costimulatory molecule expression on
skin B cells. CD1 is a key antigen-presenting and regulatory molecule related to MHCI
that presents lipid molecules to CD1-restricted T cells, such as NKT cells and some γδ T
cells, both of which are known to play important roles in the immunosurveillance and
immunoregulation of the skin (192, 193). Skin B cells from granuloma-draining lymph (32
± 6.7%), skin granuloma (42.8 ± 9.5%), and blood (59.7 ± 7.4%) were enriched in the
expression of CD1 compared to B cells from control (uninflamed) skin lymph nodes (Fig.
4A). CD1 expression on skin and skin-draining B cells implies that they may interact with
skin NKT or γδ T cells, generating an effective cutaneous immune response.
Compared to B cells from a control (uninflamed) lymph node, B cells from
uninflamed skin displayed modestly higher expression of MHCII (Fig. 4B). A more
striking difference was observed for B7.1/B7.2 expression (determined by CTLA4-Ig
binding). B cells from uninflamed and granulomatous skin, and even more so from skin
draining lymph, expressed higher levels of B7.1/B7.2 than did lymph node B cells (Fig.
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4B). Taken together, these data suggest that skin B cells are well equipped for antigen
presentation to a variety of classical and non-classical T cells.

“Innate-like” B cells reside in and recirculate through uninflamed and inflamed
skin.
The phenotype of skin-associated B cells could give insight to the capacity to modulate
cutaneous immune responses. IgMhi expression marks more innate-like B cells such as
Marginal zone (MZ) and B1 cells capable of mounting efficient T-independent immune
responses. Interestingly, in both the uninflamed (9.3 ± 1.5%; P<0.0001) and granuloma
(7.9 ± 1.9%; P=0.0006) skin-draining lymph, we detected a significantly higher proportion
of IgMhi B cells compared with skin lymph node B cells, which contained only a negligible
population of IgMhi B cells (0.91 ± 0.21%) (Fig. 5A-B) consistent with the fact that lymph
node B cells are largely (IgMlo) follicular B cells. Furthermore, we found significantly
more IgMhi B cells in both uninflamed (P=0.002) and granuloma-draining (P=0.0295)
afferent lymph than in efferent lymph (1.46 ± 0.41%; Fig. 5A). Sheep blood contains high
numbers of IgMhi B-1-like cells (127), and as expected, we detected a large population of
B cells in the blood expressing high levels of IgM (25.33 ± 4.0%, Fig. 5A-B). Data
suggests that MZ B cells recirculate in humans (131) and MZ B cells are characterized
by high expression of CD1 (81). Based on the lower expression of CD1 and that of other
MZ B cell markers such as CD21 and CD9 on skin B cells relative to splenic MZ B cells,
we concluded that IgMhi and/or CD1+ B cells in the granuloma and granuloma lymph are
not MZ B cells (data not shown). As B-1 cells express CD1 (194), we wondered if skinassociated B cells belong to this subset. In sheep, CD11b is a marker of B-1-like cells
(127), and as such, we compared CD11b expression on the skin B cell populations.
IgMhi expressing B cells in uninflamed and granulomatous skin and skin draining lymph,
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as well as blood, expressed high levels of CD11b relative to CD11b expression levels of
total lymph node (follicular) B cells (Fig. 5C). Thus, skin-associated IgMhi B cells are of
B-1-like phenotype, constitutively traffic through skin and leave via the afferent lymph.
Because ovine B-1-like cells often express CD11c (127), we determined CD11c
expression by skin B cells and found that CD11c was expressed at higher frequencies
than CD11b in B cells traveling in skin draining lymph (Fig. 5D). The microscopic
analysis of FACS-sorted and Pappenheim-stained B cells from skin-draining lymph
revealed that the double-negative cells were comprised of mature lymphocyte of
approximately 10-µm diameter with a condensed chromatin and scant basophilic
cytoplasm (Fig. 5E). In contrast, the slightly larger (~12 µm diameter) CD11b–/CD11c+ or
CD11b+/CD11c+ lymphoid cells exhibited a more open chromatin and deeply basophilic
cytoplasm that occasionally contains a fine paranuclear Golgi clearing (Fig. 5E).
Systematic analysis of cell diameters confirmed that CD11b–/CD11c+ (12.08 ± 0.21 µm)
and CD11b+/CD11c+ (11.92 ± 0.48 µm) B cells were significantly larger than were
CD11b–/CD11c– B cells (10.06 ± 0.40 µm; P<0.0001) (Fig. 5F). The cytomorphology
suggests that CD11b or CD11c positive cells are more activated lymphoid cells in
contrast to the more quiescent morphology of the dual negative cells.

Antibody titers and ASCs increase locally during chronic inflammation.
Antibodies secreted by effector stage B cells, antibody-secreting cells (ASC), are critical
to host defense but also to autoimmunity and allergy. Having found that B cells
accumulate in the chronically inflamed skin, we wondered whether an increase in
localized antibody titers was a functional consequence. To address this, we compared
total Ig levels in the plasma of blood and lymph and found that while blood titers were
always highest, antibody titers in the granuloma draining lymph were significantly higher
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than those of the uninflamed skin draining lymph (Fig. 6A, p=0.016). To confirm that the
increased titers correlated with antibody production in the tissue, we enumerated ASCs
by ELISPOT assays and found that ASCs also accumulated (~400-fold on average) in
the chronically inflamed skin relative to control skin of the same animals (Fig. 6B-C).
Antibody titers in the draining lymph did not increase to the same extent as the ASCs in
the tissue. This is not unexpected as the cannulated lymphatics drain a much larger site
than just the granuloma region, causing the antibody titers to be a diluted average of the
entire drainage site.
Even though chronic inflammation is generally not associated with increased
vascular leakage, we excluded that the increased antibody titers were not simply a result
of increased blood vascular permeability. We analyzed Ig levels in skin-draining lymph
plasma during acute CFA-induced inflammation (<24h), which is characterized by drastic
blood vascular leakage and edema, and found that antibody titers did not increase (data
not shown). This verifies that poor vessel integrity was not responsible for the increased
Ig titers in the granuloma lymph. Based on these data we conclude that B cell
accumulation in the chronically inflamed skin leads to increased localized antibody
production and titers that are potentially important in the defense against skin pathogens
but that could also be harmful during autoimmunity.

CD21 and L-selectin expression on skin-associated B cells
Expression of CD21 and L-selectin marks a pool of B cells that preferentially recirculates
between blood and lymph nodes, leading to their enrichment in efferent lymph (184). In
contrast, the lack of CD21 and L-selectin is associated with preferential migration to the
spleen, a low ability to leave the blood, and an ensuing enrichment in the blood (184).
We compared B cells in the afferent lymph draining the skin to these B cell pools and
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found that the majority of B cells in afferent lymph were positive for CD21 (55.72 ±
6.94%) and L-selectin (70.64 ± 6.67%), as was a smaller population B cells in the blood
(CD21, 37.54 ± 5.31; L-selectin, 54.38 ± 8.92) (Fig. 7). In contrast, only a small
population of B cells isolated from the skin expressed either CD21 (16.5 ± 3.17%) or Lselectin (13.35 ± 3.34%) (Fig. 7). Thus CD21 and L-selectin expression does not clearly
delineate skin B cells into known recirculating and non-recirculating B cell pools.

Skin B cells utilize a unique repertoire of trafficking receptors
We next examined adhesion molecule expression that denotes skin homing versus gut
homing lymphocytes. As previously shown and specific to skin-tropic T cells (22), CD4 T
cells in skin-draining lymph expressed high levels of both alpha-4 and beta-1 integrins as
well as low levels of beta-7 integrin (Fig. 8A, top row). As expected (22), CD4 T cells in
the blood contained a population of alpha-4 and beta-7 high expressing cells, consistent
with the presence of gut homing T cells (Fig. 8A). Unexpectedly, lymph-borne B cells
showed equal or lower expression of alpha-4 and beta-1 but higher levels of beta-7
integrin relative to co-isolated skin-draining CD4 T cells (Fig. 8A). CD4 T cells from the
blood and skin lymph had distinct integrin expression patterns, which are consistent with
known phenotypes of skin (α4β1hi, α4β7lo) versus gut (α4β1lo, α4β7hi) homing. However, B
cells from blood and lymph had near identical expression patterns of the integrins
examined (Fig. 8A). To address whether the integrin expression pattern for B cells is
homogenous throughout the body, we examined B cells traveling in the mesenteric
efferent lymph (Fig. 8B). We found that mesenteric lymph B cells, but not blood or skin
lymph B cells, were uniformly high in the expression of beta-7 integrin (Fig. 8A-B), which,
when paired with alpha-4, is required for gut homing. Thus, B cells at different anatomic
sites exhibit distinct integrin expression patterns such as known gut versus skin homing
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phenotypes. Furthermore, whereas approximately half (57.1 ± 9.5) of the skin-draining
CD4 T cells expressed E-selectin ligand, B cell expression of this skin homing molecule
was enriched compared with blood B cells but significantly lower relative to skin T cells
(14.8 ± 4.9, P=0.02, paired t test, Fig. 8C).
The chemokine receptor requirements for entry into the skin have been well
studied for some leukocyte subsets. For T cells CCR4, CCR8, and CCR10 are important
in mediating entry into skin in mice and humans (20, 30). Data implies that CCR6
mediates the migration of Langerhans cell precursors into skin (158, 195). We therefore
tested if skin-associated B cells migrate in response to ligands for these skin-associated
chemokine receptors in an in vitro chemotaxis assay. In contrast to co-isolated CD4 T
cells, B cells traveling in skin draining lymph were not responsive to CCL17, CCL1, and
CCL28, ligands for CCR4, CCR8, and CCR10, respectively (Fig. 8D). Surprisingly, skin
B cells migrated well in response to the CCR6 ligand CCL20. Taken together, the data
suggest that B cells use CCR6 or alternative chemoattractant receptors for their
recirculation through skin.

Discussion
B cells are capable of many effector functions beyond antibody production; however,
their role in most extralymphoid tissues has yet to be defined. Recent studies show that
B cells accumulate in the inflamed skin in a variety of diseases, including cancer,
autoimmunity and infection (180, 196, 197). To shed light on the role of skin-associated
B cells, we examined the migration and phenotype of cutaneous B cells.
It is often assumed that B cells do not reside in or recirculate through the skin in
the absence of inflammation (178). In contrast to that assumption, we found that B cells
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are present in both uninflamed skin-draining afferent lymph and the uninflamed flank
skin itself (Fig 1A); thus B cells continuously traffic through the skin and are a steadystate population of this organ. Studies by others showed that B cells travel in the afferent
lymph draining from uninflamed human skin (177), suggesting that B cells are
characteristic of mammalian skin.
Our study further revealed that, during chronic inflammation, skin-draining B cells
exhibit the most consistent and greatest relative increase of all lymphocyte subsets
studied (CD4, CD8, and γδ T cells, and B cells) (Fig. 2). Importantly, B cells dramatically
accumulated in the inflamed skin to constitute nearly half of all lymphocytes in the
granuloma (Fig. 3). Large numbers of B cells are often found in M. tuberculosis
granulomas of the lung, in which they play a protective role by aiding in the recruitment
of other immune cells (198). B cells may fulfill a similar role in chronic skin inflammation.
We found increased expression of antigen-presenting and costimulatory molecules on
skin-associated B cells relative to lymph node B cells (Fig. 4). Consequently, B cells in
afferent lymph may migrate into lymph nodes to activate naïve T cells, whereas B cells
in the granuloma may be capable of stimulating effector/memory T cells at the site of
inflammation, thereby boosting the inflammatory response. In that regard B cell antigen
presentation could be of critical importance because B cells are able to present their
cognate antigen efficiently at very low concentrations relative to other APCs (199).
B cells are key players in many autoimmune diseases, even in those that were
primarily considered T cell-mediated, such as multiple sclerosis (180, 200). Furthermore,
B cell depletion in humans has revealed a role for B cells in cutaneous disorders,
including bullous skin diseases (180) and atopic eczema, a condition not typically
associated with autoantibody (201). Moreover, in some systemic autoimmune disorders
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with cutaneous manifestations, such as systemic lupus erythematosus, the clinical
improvement following B cell depletion does not always correlate with a decline in
autoantibody titers, suggesting that B cell functions other than antibody production, i.e.
antigen presentation and cytokine production, are critical in cutaneous immune
responses (180).
B-1 cells are typically located within the peritoneal and pleural cavities, sites of
constant microbial exposure. By producing natural antibody and rapidly mounting Tindependent immune responses that result in the production of broadly specific, crossreactive IgM, B-1 cells are important early in the immune response against pathogens
(81). Our analysis revealed that a subset of skin and skin-draining lymph B cells is IgMhi
CD11bhi (Fig. 5), and thus resembles B-1-like cells that were previously described in
sheep blood (127). 90% of efferent lymph lymphocytes are blood-derived and only 10%
originate from the afferent lymph (8, 11). Therefore, the appearance of IgMhi CD11b+ B1-like B cells in skin, skin draining lymph and blood in combination with their relative
absence in lymph nodes and efferent lymph (Fig. 5) suggests that a population of B-1like B cells migrates between blood and skin and egresses via the afferent lymph and
that only few B-1-like B cells recirculate between blood and lymph nodes.
We propose that B-1 like cells recirculate through skin as a first line of defense
against pathogens that invade via the epidermis. In line with the notion of a skin
surveying B-1 like B cell, B-1 cells were shown to recirculate between the body cavities
and blood (121) and to migrate into the lung and draining lymph nodes during pulmonary
infection (92, 202). Additionally, B-1 cells migrate from the peritoneal cavity to the skindraining lymph nodes during the course of cutaneous contact hypersensitivity (105). Our
study extends these findings by showing that B-1-like cells recirculate through the skin
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itself, thus, are well positioned to participate in protective as well as harmful cutaneous
immune responses.
Antibodies secreted by differentiated B cells, including B-1 cells, are key effector
molecules in the defense against invading pathogens; however, they can also be
pathogenic in autoimmunity and allergy. Total Ig titers in skin draining lymph were well
below that of the blood, suggesting that antibody does not fully penetrate and/or saturate
the skin. This finding could be of great consequence to the many disease treatments that
utilize depleting antibody if intravenous administration does not effectively reach the
skin. We found that B cell and ASC accumulation in the skin during chronic inflammation
leads to increased localized Ig titer (Fig. 6A), either directly or as a combination of
increased ASCs and of higher antibody production on a per cell basis. This localized
antibody production in the skin likely represents a mechanism by which the body clears
or contains an ongoing skin infection and ensures protection against reinfection. While
an accumulation of pathogen-specific ASCs and B cells would be beneficial, the
recruitment of autoreactive B cells to the site of inflammation with subsequent localized
antibody production has the potential to exacerbate inflammation in autoimmune
diseases that affect the skin such as cutaneous lupus erythematosus or pemphigus.
Young and colleagues previously found that efferent lymph B cells segregate into
recirculating and non-recirculating cell pools. The lymph node recirculating pool was
marked by expression of CD21 and L-selectin. Conversely, CD21 and L-selectin doublenegative B cells were excluded from lymph node recirculation and preferentially migrated
into the spleen (184). Consistent with the concept that leukocytes in the afferent lymph
are migrating to the lymph node, we find that slightly fewer afferent lymph B cells costain for both of these markers (Fig. 7) than what was shown for efferent lymph B cells
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(184). It is conceivable that the CD21¯ L-selectin¯ afferent lymph B cells do not migrate
from the blood to lymph nodes via high endothelial venules, and instead enter the lymph
node by way of (skin) tissue and afferent lymph. Surprisingly, a lower percentage of B
cells isolated from the uninflamed skin, but not the granuloma, were positive for both
CD21 and L-selectin. The difference in CD21 and L-selectin expression between B cells
residing in skin and B cells exiting the skin suggests that they represent two different
populations: one that is sessile in and one that recirculates through skin. Alternatively,
these markers could be upregulated once a B cell exits from skin. This difference is only
observed in uninflamed skin, implying that the lack of CD21 and L-selectin denotes a
skin resident population that is diluted as B cells traffic to and accumulate in the
chronically inflamed skin.
While the mechanisms by which T cells migrate into skin are well characterized
and critical to cutaneous inflammation and immunosurveillance (29), little is known about
B cell migration into skin. Here, we observed that B cells in the skin draining lymph
expressed high levels of alpha-4 and beta-1 integrins and a smaller subset bound Eselectin (Fig. 8). Thus, skin B cells are well equipped with adhesion molecules typically
associated with T cell homing to the skin. Importantly, CD4 T cells draining the skin were
responsive to chemokine ligands for CCR4, CCR10, and CCR8 (Fig. 8D), chemokine
receptors key to the recruitment of T cells into skin in mice and humans (203). Ligands
for CCR4, CCR10, and CCR8 were also able to attract skin draining CD4 T cells in the
sheep, implying that the mechanism of skin homing via these receptors is evolutionary
conserved. However, co-isolated ovine skin B cells were unresponsive to ligands for
these receptors (Fig. 8), suggesting that B cells utilize alternative chemokine receptors
to migrate into the skin.
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The CCR6 ligand CCL20 is constitutively expressed in the epidermis and by
dermal endothelial cells and presumably mediates the recruitment of Langerhans cell
precursors into skin (158). While most blood-borne B cells express surface CCR6, they
lack responsiveness to CCL20 but acquire it upon B cell receptor stimulation (204). Our
study shows that skin-draining B cells are spontaneously responsive to CCL20; thus, the
CCR6-CCL20 axis is a likely candidate for mediating B cell localization to skin.
Rituximab, an antibody to human CD20, depletes circulating B cells to effectively treat B
cell lymphomas and autoimmune disorders, including skin diseases (180). However, the
efficacy of B cell depletion in many extralymphoid sites, including the skin, remains
unknown. As an alternative approach, targeting specific trafficking molecules, such as
CCR6, to restrict B cell entry into effector sites could reduce disease pathology while not
affecting general B cell function.
In conclusion, our data show that innate-like and conventional B cells with the
potential to activate T cells or produce antibody reside in and/or continuously recirculate
through healthy and inflamed skin. Thus, our study reveals a so far unappreciated role of
skin B cells as potential regulators of cutaneous immunity and inflammation.
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Figure 1. B cells reside in and recirculate through uninflamed skin. Lymphocytes from
uninflamed skin, uninflamed skin-draining afferent lymph and peripheral blood from adult sheep
were analyzed. (A) Flow cytometric analysis of the expression of pan-B-cell marker recognized by
clone 2-104 and MHC class II on gated lymphocytes from uninflamed skin, uninflamed skindraining afferent lymph, and blood. One representative animal of at least 5 (lymph and blood) or 3
(skin) individually analyzed animals is shown. (B-C) Pappenheim-stained cytospins of either
unfractionated (B) or MACS-positively enriched for pan B cell marker 2-104 (C) skin-draining
lymph.
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Figure 2. B cell traffic increases in chronic skin inflammation. Chronic cutaneous
inflammation was induced by subcutaneous injection of CFA into sheep flanks. Ovine
lymph was collected after catheterization of draining afferent lymphatics of uninflamed
(control) or chronically inflamed (3-5 weeks after induction of inflammation) skin. (A)
Numbers of cells collected from skin draining afferent lymphatics over time (cell output)
were determined for CD4, CD8, and γδ T cells, and B cells. Data points show the mean ±
SEM of multiple time points analyzed for cell output from control (uninflamed) and
granulomatous skin. One representative animal out of at least 4 individually analyzed
animals is shown. (B) The percentage of lymph-borne CD4, CD8, and γδ T cells, and B
cells draining control and granulomatous skin showing all individually analyzed animals.
Connected lines indicate individual animals (C) Flow cytometric analysis of CD4 and B
cells on gated lymphocytes. Numbers indicate the percentage of positive cells in the
specified gates. One example staining of at least 8 individually analyzed sheep is shown.
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Figure 3. B cells accumulate in chronically inflamed skin. Healthy control skin and CFAinduced skin granulomas were analyzed 3-5 weeks post induction of inflammation. (A) The
percentage of (pan-B cell marker) 2-104-reactive B cells among total lymphocytes isolated from
uninflamed and granulomatous skin was determined by flow cytometry for all animals (N=5). (B –
F) Immunofluorescence staining of 6 µm thick frozen skin sections. One representative staining of
+

IgM (FITC, green) cells and DAPI (blue) in uninflamed (B and C) or granulomatous (D-F) skin of
a minimum of 4 animals analyzed each.
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Figure 4. Skin B cells are well-suited for antigen presentation. Lymphocytes from skin
granuloma and control skin, skin-draining afferent lymph and peripheral blood were isolated from
sheep (A) Flow cytometric analysis of CD1 and isotype control staining on gated B cells (pan-B+

+

cell marker 2-104 , MHCII lymphocytes) from skin granuloma-draining afferent lymph and blood.
Numbers indicate percent positive B cells. (B) Flow cytometric analysis of MCHII expression and
CTLA4-Ig binding (B7.1/B7.2 expression) on B cells isolated from lymph node and skin
granuloma, control skin, and skin-draining lymph. One representative animal of 4 (CD1), 7
(MHCII), or 6 (CTLA4-Ig) individually analyzed animals is shown.
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Figure 5. Larger B cells and B1-like B cells recirculate through the skin. Lymphocytes from
skin- draining afferent lymph, control skin-draining lymph node, blood, and skin were isolated
hi

lo

from sheep. (A) The relative distribution of IgM , IgM , and IgM
+

neg

among B cells (pan-B-cell

+

marker 2-104 , MHCII lymphocytes) from different tissues based on flow cytometry. Data points
represent the mean ± SEM of 4-8 individually analyzed animals per tissue. (B) One
representative staining of IgM expression on B cells from control (uninflamed) skin- and skin
granuloma-draining lymph, control skin lymph node, and blood is shown. (C) Flow cytometric
hi

analysis of CD11b expression on skin, lymph, and blood IgM B cells compared to total lymph
+

+

node B cells (pan-B-cell marker 2-104 , MHCII lymphocytes). One representative animal of at
least 3 (control skin) or 4 (all other tissues) individually analyzed animals is shown. (D) Flow
cytometric analysis of CD11b and CD11c co-expression on blood and afferent lymph B cells. (E)
+

+

B cells (live, lymphocytes, MHCII , pan B cell marker ) were FACS-sorted according to specified
CD11b and CD11c expression and cytospun and Pappenheim-stained for cytological evaluation.
(F) Quantification of cellular diameters from E. One representative of a minimum of 3 individually
analyzed lymph samples is shown (D-F).
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Figure 6. Antibody titers and ASCs increase locally during chronic skin inflammation. (A)
ELISA of total Ig antibody titers in plasma from blood and afferent lymph draining control skin or
chronically inflamed skin (granuloma). (B) ELISPOT assay analyzing total Ig secreting cells in
blood, uninflamed control, or granulomatous skin of the same animal. (A and B) Individual
animals are identified by unique symbols; bars represent the mean ± SEM. (C) Developed
5

4

ELISPOT wells analyzing 2x10 and 1x10 cells/well from uninflamed control and granulomatous
skin, respectively. One representative animal of 3 is shown. *, p<0.05.
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Figure 7. CD21 and L-selectin expression on skin-associated B cells. Flow cytometric
analysis of CD21 (top row) or L-selectin (bottom row) on gated B cells (solid line) and total
lymphocytes (shaded). Numbers indicate the percentage of positive B cells in the specified gates.
One representative animal of at least 5 individually analyzed animals is shown.
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Figure 8. Homing receptor expression and chemotactic responsiveness of skin B cells. (A)
Flow cytometric analysis of alpha-4, beta-1, and beta-7 integrins on gated CD4 T cells and B cells
from afferent lymph draining uninflamed skin (solid line) or blood (dashed line). One
representative animal of at least 6 individually analyzed animals is shown. (B) Flow cytometric
analysis of alpha-4 and beta-7 integrins on gated CD4 T cells and B cells from mesenteric
efferent lymph (solid line) or blood (dashed line). One representative animal of at least 4
individually analyzed animals is shown. (C) Flow cytometric analysis of E-selectin ligand
expression on gated CD4 T cells and B cells from afferent lymph draining uninflamed skin or
blood. Shaded line represents control staining in EDTA. One representative animal of at least 3
individually analyzed animals is shown.
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Chapter 4: Skin B-1 B cells can secrete IL-10 and require α4 integrin
for cutaneous localization
Abstract
B1 cells are innate-like lymphocytes that provide important effector functions
during infection and inflammation by rapidly secreting pro- and anti-inflammatory
cytokines and efficiently mounting T cell-independent (TI) antibody responses. Despite
their importance, however, the migratory paths, target organs, and trafficking molecules
involved in B1 cell migration are poorly-defined. Our previous studies have
demonstrated the presence of B-1-like cells in the skin and skin draining lymph of sheep.
Here, we extend our studies to mice and humans to reveal that innate-like B cells are a
so far uncharacterized part of the normal cutaneous immune system. In addition, we find
that in mice, B1 cells, unlike conventional follicular B2 cells, are efficiently deployed into
the inflamed skin through differential expression of the trafficking molecule α4β1 integrin
(VLA-4). Furthermore, innate B cells are a contributing source of IL-10 in both IL-10reporter mice and normal human skin. In summary, the data supports a model in which
B1 cells, through the constitutive expression of inflammation-seeking homing molecules,
are poised to migrate into barrier sites, including the skin, where they rapidly provide
requisite effector functions, such as production of IL-10, and fulfill a so far unappreciated
role in skin immunity.
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Introduction
B-1 B cells are an innate B cell subset critical in homeostasis, as well as during
infection and inflammation. B-1 B cells are responsible for the vast majority of circulating
IgM (100), and this natural IgM helps maintain tissue homeostasis and control
inflammation (205). B-1 B cells are also capable of rapidly secreting IgM in response to
inflammation and viral and bacterial infections (91 Itakura, 2005 #205, 104). In addition
to antibody production, B-1 B cell effector functions include the production of cytokines
and antimicrobial factors, thereby bridging the gap between innate and adaptive immune
responses. While the antibody-dependent functions of B-1 B cells are relatively well
established, their antibody-independent activities are only beginning to be explored. For
example, in a recent study describing “innate response activator B cells,” a subset of
GM-CSF-producing innate-like B-1 B cells is essential for neutrophil activation, bacterial
clearance, and host survival during sepsis (117). Another study reveals the phagocytic
and microbicidal potential of mouse peritoneal B-1 B cells. These cells are capable of
phagocytosing and killing bacteria with subsequent antigen presentation to CD4 T cells
(112). IL-10 production by B-1 cells has also been described in a variety models ((116,
206); reviewed in (207)), and enables B-1 B cells to play a key role in regulating immune
responses.
B-1 B cells primarily reside within the peritoneal and pleural cavities (81, 89), but
recent work demonstrates that this is not a sessile population. B-1 B cells recirculate
through the peritoneal cavity utilizing CXCR5, CCR7, and S1P1 (121-123) with
peritoneal B-1 B cells preferentially migrating to the peritoneum compared to B-2 B cells
(121). B-1 B cells can rapidly exit the peritoneal cavity and migrate to distant tissues,
such as the spleen (98), intestine (118), influenza infected lung (92), and skin-draining
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lymph nodes in contact hypersensitivity (105). Inflammation-induced exit from the
peritoneal cavity coincides with the down regulation of alpha-4 and beta-1 integrins,
which are proposed to retain peritoneal B-1s within the peritoneum (118). Although
chemokine requirements for B-1 cell entry and exit from the peritoneum have been
described, other trafficking molecules used in peritoneal recirculation, as well as the
molecules used in migration to most other tissues, remain unknown.
We recently identified a population of B-1-like B cells in the skin and skin draining
lymph of sheep (2). As B-1 B cells have a myriad of functions and have been found in
other barrier sites in the mouse (92, 118), we followed up our ovine study by
investigating this subset in mouse skin. We have found that B cells, both B-1 and
conventional follicular B-2 B cells, are a so far uncharacterized part of the normal
cutaneous immune system. In addition, we find that B-1 B cells, unlike B-2 B cells,
efficiently home into the inflamed skin, where they are capable of secreting IL-10.
Consistent with this migration preference, B-1 cells and follicular B cells exhibit
differential expression of the trafficking molecule α4β1 integrin (VLA-4), which mediates
B-1 cell entry into the inflamed skin. In summary, the data support a model in which B-1
B cells are poised to migrate into barrier sites, including the skin, where they can provide
rapid effector functions, such as IL-10 production, and fulfill a so far unappreciated role
in skin immunity.
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Materials and methods
Animals and induction of cutaneous inflammation
Sex- and age-matched CD45.1 or CD45.2 wild-type C57BL/6 (The Jackson Laboratory,
Bar Harbor, ME) or Vert-x IL-10 reporter mice (116), provided by Christopher Hunter
(University of Pennsylvania, Philadelphia, PA) were used for all mouse experiments. All
mice were between 8-16 wk old. To induce chronically inflamed skin, 50-100 µL
Complete Freund’s Adjuvant (CFA) emulsified 1:1 with sterile saline was injected
subcutaneously into the flank skin of mice.
Human tissues
Purified human peripheral blood mononuclear cells (PBMCs) were obtained from the
Human Immunology Core at the University of Pennsylvania under an Institutional
Review Board–approved protocol. Declaration of Helsinki protocols were followed and all
donors gave written, informed consent. Fresh normal, healthy human skin was provided
by the University of Pennsylvania’s Skin Disease Research Center (SDRC) under its
Institutional Review Board-approved protocol. Human skin samples were obtained from
skin surgery procedures and would have otherwise been discarded. Before use, all
samples were de-identified.

Cell isolation
Leukocytes were isolated from shaved human or mouse skin samples by mechanical
disruption followed by 2- 30 minute enzymatic digestion steps using 0.1mg/mL DNase I
(Roche) and 0.13U/mL Liberase TM (mouse skin, Roche) or 0.26U/ml (human skin,
Roche) in HBSS at 37°C. Between digestion steps, released cells were collected and
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washed in assay media (RPMI 1640 medium [Invitrogen] with 5% newborn calf serum
(NCS, [Hyclone Laboratories]). After the second digest, remaining partially-digested skin
was mashed through a 100 µM cell strainer (BD Bioscience), washed with assay media,
and passed through a final 70µM cell strainer (BD Bioscience). Leukocytes were isolated
from the small intestine, as described (208). Peritoneal cavity cells (PerCs) were isolated
by washing the peritoneal cavity with 5-10mL PBS (Invitrogen). Cells were released from
lymph nodes and spleens by passage through 70µM cell strainer. PMBCs were isolated
from mouse blood by gradient centrifugation with Histopaque-1083 (Sigma-Aldrich) as
per manufacturer’s instructions.
Cell stimulation and flow cytometry

To reduce non-specific surface staining, mouse cells were preincubated with rat IgG
(Jackson ImmunoResearch) and mAb to CD16/ CD32 (2.4G2; UCSF Monoclonal
Antibody Core); human cells were preincubated with rat IgG (Jackson ImmunoResearch
Laboratories), and human FcR Binding Inhibitor (eBioscience). After blocking, the mouse
cells were labeled with the following biotinylated or fluorochrome- conjugated (FITC,
Pacific Blue/eFluor450, PE, Alexa Fluor 647, allophycocyanin, APC-AF750, PerCpeFluor710, PE-cyanin 7) anti-mouse monoclonal Abs from eBioscience: CD45.1 (A20),
CD45.1 (104), CD45 (30-F11), CD19 (1D3), CD43 (S7), B220 (RA3-6B2), alpha-4
integrin (R1-2), beta-1 (HMB1-1), CD4 (RM4-5), CD11b (M1/70), CD5 (53-7.3). High
affinity beta-1 (9EG7, BD Biosciences) was conjugated using the Alexa Fluor ® 647
Antibody Labeling Kit (Molecular Probes) according to manufacturer’s instructions.
Human cells were labeled with the anti-human monoclonal antibodies specific for CD3
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(SK7), CD19 (HIB19), CD20 (2H7), CD45 (2D1) from eBioscience and CD27 (L128) and
CD43 (1G10) from BD Bioscience.
To detect IL-10 producing cells by GFP expression in Vert-x IL-10 reporter mice (116),
cells were polyclonally stimulated 10µg/mL LPS (Sigma), 10ng/mL PMA (Sigma), and
500ng/mL ionomycin (Sigma) for 5 h with the addition of 10 µg/mL brefeldin A (Sigma)
and 2µM monensin (eBioscience) during the last 2 h. Cells were washed, stained with
surface markers and analyzed without fixation. Human cells were similarly stimulated but
with only PMA and ionomycin, fixed for 20 minutes in 2% paraformaldehyde,
permeabilized in 0.5% saponin, and stained with anti-human IL-10 (Miltenyi Biotec, clone
JES3- 9D7).
Dead cells were excluded with LIVE/DEAD® Fixable Aqua Dead Cell marker (Invitrogen)
used according to manufacturer’s instructions. For cell surface staining with biotinylated
Abs, PE-Texas Red conjugated streptavidin (Invitrogen) was used as a secondary
reagent. Staining of digested skin was performed in parallel with that of digested and
undigested lymph node to verify that Ags were not cleaved during the cell-isolation
process. Samples were acquired on a BD LSRII or LSRFortessa using FACSDiva
software (BD Biosciences), and analyzed with FlowJo software (Tree Star, Ashland,
OR). Gates were set according to appropriate isotype-control staining. Unless otherwise
indicated B-1 B cells are pregated on live, CD45+, CD19+, CD43+, B220lo/neg
lymphocytes, and B-2 B cells pregated on live, CD45+, CD19+, CD43neg, B220+
lymphocytes.
Short-term radioactive homing experiments
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PerCs were isolated from donor mice and enriched for B-1 B cells to ≥95% purity by
negative selection with biotin microbeads after labeling with anti-CD23 and anti-F4/80
biotin (Miltenyi Biotec) followed by positive selection by CD19 microbeads (Miltenyi
Biotec). Cells were labeled with

111

Indium, as described (209). 2.6-2.7*105 B-1 cells were

transferred IV to each recipient animal. 15h after transfer, animals were euthanized, and
the following tissues were collected: blood, PerC, skin, spleen, skin-draining LN,
mesenteric LN, lung, liver, and the rest of body without the tail (injection site). The
accumulation of B-1 cells within specific organ is measured as a percentage of the
radioactivity recovered from all tissues from an individual mouse.
Short-term florescent homing experiments and antibody blockade
Leukocytes were isolated from PerCs and spleens of donor animals and differentially
labeled with either CFSE (Molecular Probes) or Cell Proliferation Dye eFluor® 670.
Labeling was achieved by incubating 107 cells/mL HBSS with 25 mM HEPES and 0.4
µM CFSE or 5 µM eFluor670 for 10 min at 37 ̊C. Both the eFluor670 and CFSE labeling
reactions were stopped by washing 1x in FBS, 1-2x in assay media, and 1x in PBS. 1.54*106 PerCs and splenocytes adding up to 107 cells (for a total of 107 cells) were injected
IV into recipient mice. 12-15h after transfer single cell suspensions were analyzed for
transferred cells (identified by fluorescent labels) and total number of cells were either
counted by hemocytometer with trypan blue exclusion (skin and small intestine) or
determined by flow cytometry with a fixed number of polystyrene beads (Polybead;
Polysciences). In order to compare the relative migration efficiency of PerC B-1 cells to
splenic B-2 cells, the ratio of homed CFSE+ to eFluor670+ cells was determined by flow
cytometry and normalized to the input population. To control for the effects of the cell
labeling, the dye used on each population was switched and no effect on migration
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(absolute or relative to the two populations) was observed. In homing experiments
testing the effect of alpha-4 integrin blockade, the mixed population of differentially
labeled PerCs and splenocytes were divided in two input populations. One group was
resuspended in 50 µg anti-alpha-4 (PS/2) and transferred into mice that also received
300 µg PS/2 IP, and the other was resuspended in 50 µg rIgG2b (LTF-2) and transferred
into mice that also received 300 µg LTF-2 IP. PS/2 and LTF-2 were obtained from the
UCSF Monoclonal Antibody Core.
Statistical analysis
All statistical analyses were calculated using GraphPad Prism software. Unless
otherwise indicated, all values are reported as mean ± SEM. Analyses used include the
paired, non-parametric Wilcoxon signed-rank test, the non-parametric one way anova
followed by Dunns multiple comparison test, or the student’s t test, and the appropriate
statistical analysis is indicated in the figure legend. The p values < 0.05 were considered
statistically significant.
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Results and Conclusions
B-1 B cells are part of the cutaneous immune system.
We recently demonstrated that B-1-like B cells recirculate through the skin of sheep (2).
As B-1 B cells are more fully characterized in mice and their multi-functionality enables
them to be key mediators in immune responses, we followed up our ovine studies in
mice. Examination of uninflamed (control) and chronically inflamed skin revealed that B
cells are a component of the cutaneous immune system, constituting 11.62 ± 1.36%
(control) or 17.92 ± 3.88% (inflamed) of CD45+ lymphocytes (Figure 1A). This is
consistent with our observations in the ovine model, although murine B cells comprise a
larger proportion of lymphocytes in the uninflamed skin and a smaller proportion of
lymphocytes in the same model of cutaneous inflammation. This suggests that although
the findings are similar, differences in the populations and/or functions of skin B cells
may exist between species. Phenotyping the cutaneous B cells identified a population of
CD19+, CD43+, B220lo/neg B-1 B cells in both tissues ([23.13 ± 2.7% (control) and 12.7 ±
2.8% (inflamed) of skin B cells], Figure 1B) that significantly increases in the chronically
inflamed skin (6.0*103±1.4*103 (control) vs 2.5*104±6.1*103 B-1 B cells per gram skin;
Figure 1D). These B-1s were a heterogeneous population with 62.62±4.4% (control) and
53.42±2.15% (inflamed) expressing CD5 and 42.0±46% (control) and 31.45±3.0%
expressing CD11b (Figure 1C). Interestingly, skin B-1 B cells more closely resemble
peritoneal B-1 cells in their expression of CD11b, although others have shown that B-1 B
cells lose expression of CD11b after leaving the peritoneum (81, 119). CD11b can pair
with CD18 to form complement receptor 3/Mac-1, and its expression on B-1 B cells has
been correlated with their ability to form doublets (210). However, the functional
relevance of B-1 B cell doublets and the importance of CD11b in survival or migration
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outside the peritoneum have not been addressed. Having identified B and B-1 cells in
the skin of mice, we investigated whether cutaneous B cells were more a more broadly
conserved component of the skin immune system by examining B cells in human skin
samples. B cells are much less frequent in human PBMCs (211) than in sheep or mice.
Similarly, we were able to find a smaller, but consistent population of B cells in the
human skin (Figure 1E and G). The existence of a B-1 B cells in currently under debate
(129-132) as the described B-1 B cells are phenotypically similar to other B cell subsets.
However, innate functions have been described for the human B-1 subset (129, 133,
134), and as such, we investigated whether any of the cutaneous B cells expressed
markers indicative of innate B cells. Human B-1 B cells are described as CD3−, CD20+,
CD19+, CD27+, CD43+, CD70−. The digestion process required to isolate skin
lymphocytes causes cleavage of the CD70 epitope, but the other markers of this subset
were used in the analysis. Using this scheme, we were able to detect a population of B1-like B cells in human skin (Figure 1F-G). Having established B-1 and B-1-like B cells
were present in the skin of mice and humans, we assessed the function potential of
murine skin B-1 B cells. Using the Vert-X IL-10 reporter mice (116), we found that like
peritoneal B-1 B cells (114), skin B cells are capable of secreting IL-10 upon stimulation
(Figure IH-I). Furthermore, analysis of stimulated B cells isolated from human skin
showed that some skin B cells are also capable of producing IL-10.
The function of B cells in skin diseases and autoimmune disorders is not well
understood. Depletion of systemic B cells in humans with Rituximab has improved
clinical manifestations of many autoimmune diseases, such as bullous skin diseases,
systemic lupus erythematosus, and psoriasis (180). The exact mechanism of this
improvement is as yet unclear. Although autoantibody indicative of many autoimmune
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disorders and can play a role in disease manifestation, a decline in autoantibody titers
does not always coorelate with disease remission (212, 213). Furthermore, other groups
have found that after B cell depletion, there is also a decline in self-reactive CD4 T cells.
As such, it is likely that B cell depletion simultaneously intervenes at many points in the
disease pathway, possibly by depleting multiple subsets of B cells, including innate B
cells. Intriguingly, psoriasis, a cutaneous autoimmune disorder, is characterized by low
IL-10 levels, and topical IL-10 treatment improves disease (214). Furthermore, recent
cases have been reported where B cell depletion either induced or worsened psoriasis
(215, 216). Taken together, these studies suggest that proper regulation of B cell derived
IL-10 is critical to human skin disease.

Peritoneal B-1 B cells migrate into uninflamed and inflamed skin.
Since B-1 function may be important in cutaneous disease, and the full impact of
a cell in an immune response lies at the intersection of functional capacity and
localization, we examined B-1 cell homing from the peritoneal cavity to the skin. Several
groups have shown that after LPS or TLR4 ligand stimulation, B-1 B cells rapidly exit the
peritoneal cavity (118-120), but Cyster and colleagues demonstrated that without
stimulation the rate of peritoneal B-1 cell recirculation is relatively low (121). As such, we
adopted the LPS-induced exit approach to produce a synchronized population of exiting
B-1 B cells in order to examine their ability to enter inflamed skin. Twenty hours after
transferring fluorescently labeled B-1 B cells IP and inducing their exit with LPS (Figure
2A, left), we were able to detect transferred cells in peripheral tissues (Figure 2A, right).
Interestingly, the transferred B-1s represented a similar proportion of B-1 B cells in the
inflamed skin and the small intestine, a site they’ve been demonstrated to enter (118),
though whether this is due to a B-1 B cell preference to enter the skin or potentially an
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inflamed site is unclear. To assess if B-1 entry into the skin was a result of either the
LPS inflammatory signals that induced exit or from the cutaneous inflammation, we
examined the capacity of B-1 B cells to enter uninflamed skin from the blood. Due to the
low cell numbers recovered from uninflamed skin, we employed radioactively labeled B1 B cells to analyze in vivo trafficking, as radiolabeling is more sensitive than its
fluorescent counterparts (217).

111

Indium-labeled peritoneal B-1 B cells were allowed to

migrate for 15 h, and target tissues were then analyzed by γ-counter for transferred cells
(Figure 2B, left). Importantly, we were able to detect transferred cells in the uninflamed
skin and other organs (Figure 2B, right). Although most of the

111

Indium signal was

recovered in the spleen and liver [data not shown], significantly more

111

Indium signal

was recovered in the skin than in peripheral skin-draining lymph nodes (p ≤ 0.001),
blood (p ≤ 0.001), or even the peritoneal cavity (p ≤ 0.01). This demonstrates that B-1 B
cells are capable of entering even uninflamed skin from the blood.

B-1 B cells

preferentially recirculate through the peritoneum compared to B-2 B cells (121). To
determine if B-1 B cells display a similar tropism for the skin, we differentially labeled
splenic B-2 B cells and peritoneal B-1 cells and allowed them to home into the inflamed
skin. As reported, peritoneal B-1 B cells exhibited a strong preference for migration into
the peritoneal cavity over B-2 B cells (homing index range 7.3-72.0 [peritoneal B1/splenic B-2]). Peritoneal B-1 cells also exhibited a strong skin homing preference
compared to splenic B-2 B cells (homing index range 2.0-98.2 [peritoneal B-1/splenic B2]). Despite the large range in migration preference between mice and experiments, B-1
B cells consistently demonstrated a preference to enter the peritoneum or the inflamed
skin compared to uninflamed or inflamed lymph nodes or the spleen. These data clearly
illustrate the peritoneal B-1 B cells are capable of exiting the peritoneal cavity and
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migrating from the blood into the skin. However, whether all B-1 B cells in the skin are
constantly recirculating or whether there are distinct populations of migratory versus
resident cells has yet to be determined.

Integrin α4β1 mediates B-1 cell migration into the skin
We next asked what trafficking receptors could mediate B-1 B cell migration into
the skin. We compared expression of homing receptors expressed by peritoneal B-1
versus splenic B-2 B for insights as to what could mediate the observed strong
preference for B-1 entry in the skin, and among the most differentially express receptors
were the alpha-4 and beta-1 integrins (Figure 3A, left). Analysis of B-1 and B-2
populations in the skin revealed a similar enrichment of a α4,β1-integrin bright within the
skin B-1 B cell population (Figure 3A, right). To test if this integrin could mediate B-1 B
cell migration into the skin, we performed homing experiments as before (Figure 2C)
with a blocking antibody to alpha-4 integrin or a control antibody. B-1 B cell migration to
the spleen, uninflamed or inflamed skin-draining lymph nodes was not significantly
affected (Figure 3B). In contrast, we revealed that migration into the inflamed skin and
peritoneal cavity were almost completely inhibited (p = 0.005 and p = 0.007,
respectively) when blocking alpha-4 integrin. Interestingly, there was a strong, although
not significant (p = 0.63), trend for reduced migration into the inflamed skin-draining
lymph node, which suggests that B-1 B cells can utilize α4β1 to mediate migration
inflamed lymph nodes. Alternatively, the reduction of B-1 cells in the draining lymph
node could be a result of decreased traffic through the inflamed skin, but given the
magnitude of the number of cells recovered from lymph nodes versus skin and the
relatively short time period, that conclusion is unlikely. Importantly, alpha-4 integrin
blockade selectively inhibited B-1 B cell migration but not B-2 B cell migration into the
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inflamed skin. This is in contrast to the integrin requirement for peritoneal cavity entry. It
has been shown that B-2 B cells require this α4 integrin to enter the peritoneum (125),
and has been suggested, but not shown, that B-1 B cells also require it. This dichotomy
of trafficking receptor requirements illustrates a B cell subset selective mechanism for
migration into an extralymphoid site with potential therapeutic implications.

Cutaneous B-1 B cells express high affinity beta-1 integrin
B-1 B cells utilize α4β1 integrin to enter the skin, but it has also been shown that
downregulation of these integrins mediates release from the peritoneal cavity after TLR4
ligand stimulation (118). How is it, then, that the same trafficking receptor could
simultaneously be downregulated to exit the peritoneum but then also be required to
enter a subsequent site? To address this question we considered the affinity state of the
α4β1 integrin. Low affinity integrin interactions are capable of mediating tissue retention,
but high affinity interactions are required for tissue entry (218). We utilized an antibody
for beta-1 integrin that only recognizes the high-affinity state (219), and examined high
affinity beta-1 on peritoneal B-1 B cells and splenic B-2 B cells (Figure 4A). Like the
expression pattern of α4β1, a larger proportion of peritoneal B-1 B cells expressed high
affinity beta-1 than splenic B-2 B cells. Furthermore, B-1 versus B-2 B cells in the
inflamed skin exhibited a similar staining pattern (Figure 4B). In order to address if the
high affinity confirmation of beta-1 is regulated similarly to alpha-4 and total beta-1
integrins, we stimulated peritoneal B-1 B cells in vivo with LPS. As previously published
by Fagarasan and colleagues, LPS treatment induced a significant downregulation of
alpha-4 (p = 0.0009) and total beta-1 integrin (p = 0.0006)

((118), Figure 4C-D).

Surprisingly, high affinity beta-1 was significantly upregulated (p = 0.002) after LPS
stimulation. These findings suggest that whereas downregulation of low affinity α4β1 is
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required for release from the peritoneum, high affinity α4β1 can then subsequently
mediate entry into distant tissues. Whether the high affinity beta-1 can be further
triggered or if there is a selective enrichment for B-1 cells that already express high
affinity integrin upon peritoneal exit is not clear and, further experiments will be required
to determine the regulation of α4β1 in B-1 B cells.
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Figure 1. B-1 B cells are part of the cutaneous immune system. Lymphocytes from
the peritoneal cavity, PBMCs, uninflamed (control) skin, and 3-week CFA-inflamed skin
were analyzed. (A) Flow cytometric analysis of CD4 T cells and B cells pre-gated on live,
CD45+ lymphocytes, (B) CD43+, B220lo/neg B-1 B cells gated on the above CD19+ B
cells, and (C) CD5 and CD11b expression on above gated B-1 B cells. Representative
staining from at 3-5 independent experiments with 3-5 mice each are shown. (D)
Enumeration of B-1 cells per gram uninflamed vs inflamed skin from each mouse
analyzed in (A). Significance was determined with the via Wilcoxon signed-rank test. (EG) Lymphocytes from human peripheral blood and normal skin were analyzed for (E) B
cells gated on live, CD45+ lymphocytes and (F) CD43+, CD27+ B-1-like cells from the B
cell gate of (E). Representative plots from 5 (PBMCs) or 7 (skin) human donors. (G) The
frequency of B cells (left) and B-1-like cells (right) as a percentage of lymphocytes and B
cells, respectively, in human skin for all samples analyzed. Bars represent the means ±
SEM. (H) Percentage of IL-10 producing (GFP+) B-1 and B-2 B cells of total B cells from
specified tissues of Vert-X IL-10-eGFP reporter mice after stimulation with PMA,
ionomycin, and LPS. One experiment of 3 independent experiments of at least 4 mice
with similar results is shown. (I) Representative plots showing flow cytometric analysis of
GFP expression by B-1 B cells (gated on LIVE/DEAD Fixable Aqua Dead Cell marker-,
CD45+, CD19+, CD43+, B220lo/neg lymphocytes). (J) Representative flow plots showing
flow cytometric analysis IL-10 expression by B cells in normal human skin and PBMCs
after stimulation with PMA and ionomycin (gated on LIVE/DEAD Fixable Aqua Dead Cell
marker-, CD45+, CD19+ lymphocytes). One of 4 individuals analyzed is shown.
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Figure 2. Peritoneal B-1 B cells migrate into uninflamed and inflamed skin. (A)
Experimental scheme [left] and flow cytometric analysis of CFSE-labeled donor
peritoneal B-1 B cells after IP transfer and LPS-induced exit from the peritoneal cavity
[right]. Plots are pre-gated on B-1 B cells (live, CD45+, CD19+, CD43+, B220lo/neg
lymphocytes) and gates represent the percentage of transferred B-1 B cells in each
organ. Compiled plots from one of two independent experiments with similar results are
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shown. (B) Experimental scheme [right] and homing of peritoneal B-1 B cells into
uninflamed skin [left]. Peritoneal cavity cells were MACS-enriched for B-1 B cells,
labeled with

111

Indium, and IV transferred into recipient mice. 15 h post-transfer, organs

were harvested and the redistribution of radioactivity (homing into specified tissues) was
quantified with a γ-counter. Combined analysis of 2 individual experiments with 8 mice
each. (C) Experimental scheme [left] and homing of peritoneal B-1 vs splenic B-2 B cells
into inflamed skin [middle, right]. Peritoneal and splenic B cells were differentially labeled
with fluorescent dyes and transferred IV into recipient mice that had 3-week cutaneous
CFA inflammation. The homing index of peritoneal B-1/splenic B2 (peritoneal dye+, live,
CD45+, CD19+, CD43+, B220lo/neg lymphocytes/splenic dye+, CD45+, CD19+, CD43neg,
B220+ lymphocytes) for specified organs is shown [middle]. Representative plots of the
gated input populations and those populations recovered in specified organs from one of
5 individual experiments with similar results. (B-C) Bars represent the means ± SEM;
significance was determined using an nonparametric one-way ANOVA followed by
Dunns multiple comparison test (B).
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Figure 3. Integrin α4β1 mediates B-1 cell migration into the skin. (A) Flow
cytometric analysis of alpha-4 and beta-1 integrin expression on peritoneal B-1 cells vs
splenic B-2 cells [left] and by control (uninflamed) and inflamed skin [right].
Representative plots from 2 (control skin) or 5 (all other tissues) independent
experiments with 3-5 mice each are shown. Gates represent high alpha-4, beta-1
expression. (B) Homing of peritoneal B-1 B cells (as in Figure 2C) in mice that were
treated with α4-integrin blocking antibody or isotype control. 12 h after transfer,
lymphocytes were isolated from specified organs, and the number of transferred cells
was enumerated by flow cytometry. One of two experiments with similar results is
shown. Bars represent mean ± SD, and significance was determined using student’s t
test.
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and splenic B-2 B cells from mice given 20 µg LPS or PBS IP. 6 h after treatment,
spleens and peritoneal cavity B cells were analyzed for integrin expression. One of two
experiments with similar results is shown, and significance was determined using
student’s t test.. (D) Representative expression of integrins by peritoneal B-1 B cells
from (C) treated with either PBS or LPS.
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Chapter 5: Discussion
Recirculation of γδ T cells
The recirculation and migration of innate lymphocytes is critical to their
contribution to immune responses. γδ T cells are rapidly responding T lymphocytes that
secrete cytokines, such as IL-17, earlier than their αβ T cell counterparts (167, 168) to
support the activation and mobilization of the immune response (52, 73, 166, 167). In
Chapter 1 we demonstrated that cytokine-secreting γδ T cells migrate through the skin.
In contrast to αβ T cells that utilize CCR7 to exit the skin (75, 76), γδ T cell migration into
the afferent lymph was independent of CCR7. This is in line with findings in cows (220)
and mice (73), and supports that skin exit receptor requirements of γδ T cells are
conserved across mammalian species.

Although studies have started ruling out

potential exit receptors for γδ T cells, e.g., γδ T cells do not use CCR7, mechanisms by
which skin-recirculating γδ T cells enter the skin are still unknown. CCR4 and CCR10
are important for dendritic epidermal T cell (DETC) homing into the skin (62, 63), but
these resident cells are restricted to mice, and it is unclear if epidermal γδ T cells in other
species represent a homologous cell type (44, 69). CCR4 and CCR10, as well as CCR8,
also mediate CD4 T cell migration into skin (20, 30). Thus far, ovine γδ T cells appear
unique from both DETCs and αβ T cells in their skin entry requirements, as skin-draining
γδ T cells are unresponsive to CCR4, CCR8 and CCR10 ligands. Further studies in mice
are necessary to not only elucidate the trafficking receptor requirements for γδ T cells but
also to delineate the function of skin sessile versus recirculating γδ T cells.
Many studies have investigated the role of cutaneous γδ T cells in wound healing.
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In mice, DETCs promote wound healing by the production of keratinocyte growth factors
(68, 221). In humans, epidermal Vδ1 T cells can produce insulin-like growth factor 1,
which enhances wound healing in vitro (71). Intriguingly, Vδ1 T cells are also
predominantly found in the dermis with similar levels of skin-homing molecule, CLA. A
small population of Vδ1 T cells was also detected in the blood with a subset of those
expressing CLA (71). Though in vivo functional studies in humans are exceptionally
difficult, it would be interesting to know if the small population of blood-borne Vδ1, CLA+
γδ T cells were skin-recirculating dermal γδ T cells and what the contribution of dermal
versus epidermal Vδ1 T cells is to wound healing.
It is tempting to speculate that ovine skin-recirculating γδ T cells we describe are
homologous to the IL-17+ dermal γδ T cells in the mouse. Dermal γδ T cells of mice and
skin-recirculating ovine γδ T cells not only share the ability to produce IL-17 and express
CCR6, they also both express variant TCRs (73, 170, 171). Similarly, data suggest that
mouse dermal γδ T cells can recirculate because they also localize to the skin-draining
lymph node in the subcapsular sinus (48), where afferent lymph enters the lymph node.
Although the potential for murine dermal γδ T cells to recirculate has yet to be assessed,
the ability to divide the workload of continuous immunosurveillance between resident
and recirculating subsets of γδ T cells would be advantageous to achieving consistent
and robust protection from exogenous threats. While sessile epidermal γδ T cells would
be guaranteed to be near the site of barrier breach, cell number limitations and receptor
diversity could restrict their ability to combat infection.

Accordingly, reinforcing the

protection provided by resident cells with a highly mobile, receptor-diverse population
that can also rapidly respond would permit the robust response required for barrier
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surfaces, such as the skin, that are under constant microbial attack. Furthermore, though
it is well established that memory αβ T cells exhibit tissue-specific tropisms in their
recirculation (22,	
  187,	
  222), whether the γδ T cells described in Chapter 2 are a specific
skin-recirculating subset or whether they exhibit a more ubiquitous recirculation pattern
is unclear. Preliminary data [Geherin, Debes, unpublished results] suggests that unlike
αβ T cells, γδ T cells from the skin do not preferentially return; however, additional
experiments are necessary to confirm this finding.

Recirculation of B-1 B cells
The data presented in Chapters 2 and 3 is the first description of B-1 B cells as a
part of the normal skin immune system. It furthermore demonstrated that peritoneal B-1
B cells can rapidly enter into this barrier site by relocating from the peritoneal cavity or by
migrating directly from the blood under both homeostatic and inflammatory conditions.
B-1 B cells can rapidly secrete antibody and relocate from the peritoneal cavity to the
omentum, spleen, small intestines and draining lymph nodes within hours of an
inflammatory signal (98, 105, 118-120). Itakura and colleagues demonstrated that in a
hapten model of contact hypersensitivity, within an hour of cutaneous challenge, B-1 B
cells are able to migrate from the peritoneal cavity to the spleen. They subsequently
migrate to the skin draining lymph nodes where B-1 derived hapten-specific IgM
contributes to the inflammatory response (105, 223).

As we have found that peritoneal

B-1 cells readily migrate to inflamed skin, it seems likely that in the contact
hypersensitivity model, B-1 B cells could also home to the CHS-inflamed skin and
secrete local antibody or cytokines that were not assessed in previous studies. Choi and
colleagues demonstrated that B-1 cell derived natural IgM binds the influenza virus and
is, at least partially, produced in the lung. Furthermore, this pre-existing natural antibody
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is required for full protection from lethal dose infection and is not compensated for by B-2
B cells (92, 104). The circumstances that predicate pre-existing local B-1 cell responses
versus the ability to be recruited when needed are currently unknown. However, one
could imagine that as the full characterization of the anatomic localization of B-1 cells in
extralymphoid tissues has only just begun, local responses of endogenous cells may be
more frequent than what is currently believed. It is also conceivable that differences in
the homeostatic populations within tissues and the type of inflammation may determine if
B-1 B cell subsets within the tissue can respond or require additional B-1 B cell
recruitment to fulfill their role in the immune response.
In Chapter 3 we investigated the trafficking molecule requirements of B-1 B cell
migration into the skin. Although few studies have examined B-1 B cell migration to
extralymphoid cites, several groups have reported on the requirements of B-1 B cell
recirculation into and out of the peritoneal cavity. Peritoneal B-1 B cells utilize CXCR5
and CCR7 to enter the peritoneal cavity from the blood (121-123, 224). In contrast,
integrin requirements for B-1 cell entry into the peritoneal cavity or other sites were
previously unknown. Alpha-4, beta-1 integrin, which can bind VCAM-1 and fibronectin,
has been suggested to be important for B-1 cell homeostasis in the peritoneal cavity as
MADCAM-/-/VCAM-/- double knockout mice exhibit significantly fewer B-1 B cells in the
peritoneal cavity compared to MADCAM-/- single knock-outs (125). However, whether
this decrease in peritoneal B-1 B cells is because of entry versus exit requirements or
due to survival has not been investigated. Conversely, upon exit from the peritoneal
cavity after LPS stimulation, it has been shown that alpha-4 and beta-1 integrins are
downregulated (118), and this allows B-1 B cell release from the peritoneal cavity. These
studies, as well as our findings, are summarized in Figure 1, left.
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As peritoneal B-1 B cells, which we show preferentially migrate into the skin
compared to follicular splenic B-2 B cells, express high levels of alpha-4 and beta-1
integrins compared to B-2 B cells, we investigated the role of this integrin in homing to
the inflamed skin. Not only did the majority of cutaneous B-1 cells highly express alpha-4
and beta-1 integrins, similar to their peritoneal counterparts, but treatment with a
blocking antibody to alpha-4 integrin significantly abrogated not only migration to the
inflamed skin, but it also abrogated homing to the peritoneal cavity. VCAM-1, the binding
partner to α4β1 integrin, is constitutively expressed in the skin and upregulated in
inflammation (225). As B-1 B cells from both the uninflamed and inflamed skin
expressed similar levels of α4β1 integrin, it is likely that B-1 cell homing to skin in
general is mediated by this interaction, similar to homing to the peritoneal cavity, which
was not inflamed in these experiments. As these high levels of α4β1 integrin are
suggestive of an inflammation-seeking cell, it is interesting to hypothesize that B-1 B
cells home to various inflamed tissues. Evidence for this can be found within our own
homing experiments. Alpha-4 integrin blockade caused B-1 B cell migration to the
inflamed skin-draining lymph node to be reduced to the level of the uninflamed skindraining lymph node. If this hypothesis was true, it would position B-1 B cells as a
sentinel population capable of rapid responses in all tissues, not just those considered
mucosal and/or barrier sites. Also interesting are the differential requirements of B-1
versus B-2 cell homing in the skin. Whereas B-1 B cells are acutely sensitive to alpha-4
integrin blockade, B-2 B cells were unaffected in their homing capacity to the skin.
Similarly, effector T cells are also not dependent on alpha-4 integrin to migrate into the
skin (226), suggesting a dichotomy in adhesion molecule usage for innate versus
conventional lymphocyte subsets. Further experiments should expand upon both
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uninflamed and inflamed skin-associated adhesion molecules, such as E- and P-selectin
ligand (20), to address whether 1) B-1 B cells also have some dependency on these
receptors and 2) what receptors are needed for B-2 B cell entry into the skin.
Prior to the studies conducted in Chapter 3 of this thesis, the B-1 B cell usage of
alpha-4 integrin seemed contradictory. Data suggested that it might be used by B-1 B
cells to enter the peritoneal cavity (125), but it had conversely been shown to be downregulated upon exit from the peritoneal cavity (118). Ha and colleagues also transferred
peritoneal B cells IP and gave an alpha-4 integrin blocking antibody and observed fewer
B-1 B cells in the peritoneum, concluding that alpha-4 is used to retain B-1 B cells in the
peritoneal cavity (118). Alternative interpretations of these results are that peritoneal B1s were unable to re-enter the site after exiting and that there is selective exit of alpha4hi B-1 B cells. That B-1s were shown to downregulate alpha-4 and beta-1 integrins in
response to LPS in culture negates the second alternative conclusion (118), but the
contribution of blocked re-entry to the peritoneal cavity in the decreased cellularity of that
site after alpha-4 blockade cannot be disregarded.
To reconcile our findings that B-1 B cells utilize α4β1 integrin to enter the skin but
these integrins are down-regulated to exit the peritoneal cavity (118), we investigated the
affinity state of the integrin utilizing an antibody that recognizes only high-affinity beta 1
(219). We hypothesized that down-regulation of low-affinity α4β1 could potentially
mediate release from the peritoneum but that high affinity α4β1 would be required for
entry into the skin because only the high affinity state mediates firm adhesion required
for cell entry from the blood. In vivo stimulation of peritoneal B-1 B cells with LPS led to a
down-regulation of the levels of total alpha-4 and beta-1 integrins, as described (118). In
contrast, the expression level of high-affinity beta-1 integrin increased on peritoneal B-1
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B cells, supporting divergent roles for low- versus high-affinity beta-1 integrin. Further
investigation of high-affinity beta-1 integrin on cutaneous B cells showed that the
majority of B-1 cells in the skin also express high-affinity beta-1, supporting a role in
cutaneous migration. It appears that B-1s utilize high-affinity α4β1 to enter the skin, but
the regulation of integrin affinity in this subset is not yet defined.
The finding that peritoneal B-1 B cells basally express high affinity beta-1, which
is then upregulated after LPS, leads to the hypothesis that B-1 B cells broadly recirculate
through extralymphoid sites, especially inflamed sites (Figure 1, right). However, this
also raises several questions regarding the regulation of B-1 B cells α4β1. Examination
of B-1 B cells that had exited from the peritoneal cavity would clarify if all released B-1s
express high levels of high-affinity α4β1, and as such may represent a distinct
population that is readily capable of migration into the skin or inflamed/effector sites.
Alternatively, B-1 B cells may also utilize an additional chemokine or TLR signal to
further upregulate high-affinity α4β1 expression so that any recirculating B-1 could be
induced to enter the skin or sites of inflammation. Although high-affinity integrins are
triggered by chemokine signals on the vascular endothelium in the canonical model of
lymphocyte migration (reviewed in (227)), some subsets of effector T cells can firmly
adhere to the endothelium without activation by chemokine signals (228). If the
expression of high-affinity α4β1 on B-1s is independent of chemokine signaling, it would
strongly support B-1 B cells as a rapidly tissue-surveying migratory population, well
suited to trafficking to extralymphoid sites and sites of inflammation.
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Figure 1. Recirculation of peritoneal B cells. (Left) The peritoneal cavity serves as a
reservoir for B-1 B cells. To survey tissues, B-1 cells leave the peritoneal cavity by
downregulating α4β1 integrin and exit through the omentum to the parathymic lymph
node using CXCR5 and S1P1. In order to return to the peritoneal cavity, B-1 B cells
require CXCR5, CCR7, and alpha-4 integrin. (Right) After an inflammatory signal, B-1 B
cells express more high affinity α4β1 and rapidly exit the peritoneum to home to the
spleen, gut, skin, and potentially other inflamed tissues. Migration into the inflamed skin
also requires alpha-4 integrin.

	
  

Do B-1 B cells and γδ T cell interact in the skin?
γδ T cells can recognize antigen presented by CD1 (229, 230). As we have
shown that ovine cutaneous B cells express CD1, it is possible that cutaneous γδ T cells
interact with B cells directly in the skin. Lipid antigens from bacteria, viruses, and fungi
can be presented by CD1 (231), and antigen presentation to γδ T cells, which are found
in much higher abundance in the skin than in the draining lymph nodes, could be
immunologically advantageous as γδ T cells can rapidly secrete cytokine. However,
there is little evidence in the literature regarding the interaction of B-1 B cells and γδ T
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cells. One study utilized a double transgenic mouse in which γδ T cells recognize a selfthymus leukemia antigen, and the B-1 cells recognize red blood cells (232). Only in mice
with activated autoreactive γδ T cells was there the development of B-1 antibody
mediated anemia, suggesting that non-cognate interactions, possibly through CD1,
between γδ T cells and B-1 B cells are possible. Studies coculturing various B-1 and γδ
subsets, as well as utilizing intravital microscopy in the skin, could more clearly elucidate
any potential interaction.

Innate-like lymphocytes share many characteristics between species
Our studies and others of innate lymphocytes in the skin highlight that at least
some aspects of the cutaneous immune system are conserved across mice, sheep,
cows, and humans. For example, although there are differences in the proportions of
various lymphocyte subsets, populations of γδ T cell, B-1(like), and B-2 cells can be
found in sheep, mouse, and human skin.

Also similar across species, CCR7 is

dispensable to the cutaneous exit of murine, human, bovine, and ovine γδ T cells (1, 73,
78, 233). Despite apparent functional homology in trafficking receptor usage, some
distinctions in γδ populations across species do exist, e.g. we were unable to detect an
ovine population of γδ T cells similar to the human subset of γδ T cells that upregulates
CCR7 and antigen presenting machinery (80). However, it is too early to completely
preclude the existence of this population as it is restricted to a specific subset of human
Vδ2 γδ T cells, and it is possible that a homolog has just not yet been identified in other
species.
Similarly, our studies show parallel populations of B cells in the skin of sheep,
mice, and humans. B cells in the skin and skin-draining lymph of sheep express alpha-4
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and beta-1 integrins, and we have shown that the mouse B-1 subset utilizes alpha-4
integrin to home to the skin. We have demonstrated that B-1 B cells in mouse skin are
capable of producing IL-10 after in vitro stimulation. Preliminary results from our lab also
show that cutaneous B cells in sheep and humans are capable of producing IL-10
(Geherin, unpublished observations), but further investigation is required to determine
which B cell subsets produce IL-10 in sheep and humans.

Cutaneous B cells and B cell-depleting therapies
The elucidation and preliminary characterization of B cells subsets in the skin
may change the paradigm of cutaneous immunity.

Previously disregarded in this

extralymphoid site in the absence of inflammation (29, 38, 39), realizing that B cells may
play an active role in the manifestation of autoimmunity and in response to infection in
situ could remodel our comprehension of many cutaneous diseases. Primarily due to
the advent of Rituximab; a humanized antibody to CD20 that is used to deplete B cells;
the past decade has shown significant advances in our understanding of cutaneous
autoimmune diseases that are at least partially mediated by B cells (180).
Autoantibodies are known to play a role in cutaneous autoimmune disorders, and
especially for skin-restricted diseases, such as pemphigus vulgaris and pemphigus
foliaceus, the decline in autoantibody titers after Rituximab treatment correlates well with
a decrease in clinical severity ((234-236). However, for some systemic autoimmune
disorders with cutaneous symptoms, such as rheumatoid arthritis or systemic lupus
erythematosus, improvements in clinical severity do not always correlate with decreases
in autoantibodies (212, 213). Furthermore, autoantibodies can be present in the
circulation well before onset of autoimmune disease (237, 238), which implies that
mechanisms beyond the presence of self-reactive antibodies are required for disease
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progression. The ability of B cell depletion to improve disorders that are not solely based
on autoantibodies suggests that alternative functions of B cells, such as antigen
presentation to autoreactive CD4 T cells, play a role in these diseases. This indeed was
suggested by Eming and colleagues (236) who observed that after Rituximab treatment,
pemphigus vulgaris patients also exhibited a significant reduction in desmoglein-3 (the
auto-antigen in pemphigus vulgaris) specific CD4 T cells. This mechanism was more
fully examined in mouse models of collagen-induced arthritis and autoimmune diabetes
where Bouaziz and colleagues utilized draining lymph node populations to determine
that B cells are needed for optimal CD4 T cell priming (239), but analysis of antigen
presentation in the skin has not been addressed. Interestingly, Rituximab treatment of
individuals with ectopic eczema has shown that despite near complete depletion of B
cells in the blood, B cells in the eczema lesions were only depleted by 50% (201). The
efficacy of B cell depletion by anti-CD20 treatment in a broad range of tissues has been
more thoroughly examined in mice. Similar to humans, anti-CD20 is highly effective at
depleting B cells from the blood and lymph nodes, and nearly as well as, the spleen
(240). Interestingly, despite CD20 expression, B-1a B cells in both the peritoneal cavity
and the spleen are significantly more resistant to depletion than their B-2 counterparts
(240). Whether the partial depletion of B cells in human skin lesions is due to selective B
cell subset depletion or the presence of a protective cutaneous niche remains to be seen
but may have therapeutic indications.

IL-10 in cutaneous disease
We have only begun the investigation into the function of B-1 B cells in the skin,
and proposed functions are summarized in Figure 2. Upon stimulation, the B-1 B cells
are able to upregulate IL-10 production as demonstrated by the Vert-x IL-10 reporter
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mice (116). In contrast, the B-2 B cells expressed comparatively little IL-10, suggesting
that cutaneous B-1 and B-2 B cells may exhibit differential effects in vivo. Our studies in
sheep in Chapter 2 demonstrated that B-2 B cells in the skin and skin-draining lymph
expressed CD1 and higher levels MHCII and CD80/86 than in skin-draining lymph
nodes, suggesting that these cells play a pro-inflammatory role in the skin itself and/or in
the draining lymph node (2). In contrast, the murine B-1 B cells can secrete IL-10, and
preliminary data shows a subset of cutaneous B-1 B cells expresses Blimp-1, a
transcription factor required for antibody production in B cells (reviewed in (241)),
Chapter 3; Wilson RP and Geherin SA, unpublished observation). Our lab has also
detected IgM-secreting cells in the skin, as well as increased apoptotic debris by tunnel
staining in the skin of secretory-IgM-deficient mice ((110); Wilson RP, unpublished
observations). Secreted IgM is critical for the proper clearance of apoptotic cells in vivo
(242), and subsets of B-1 B cells have been shown to have BCR specificity for such
dying cells (243). Taken together, this data eludes to a model by which cutaneous B-1 B
cells exert an anti-inflammatory roles through the secretion of IL-10 and anti-apoptotic
IgM whereas B-2 B cells provide the pro-inflammatory functions of antigen presentation
and potentially cytokine secretion.
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Figure 2. Proposed functions of B cells in the skin. Both B-1 and B-2 B cells are
found in uninflamed and inflamed skin and may contribute to opposing roles in
cutaneous immunity. Skin B-1 B cells can secrete IL-10, and possibly IgM, supplying
anti-inflammatory mediators in skin maintenance and immune responses. Conversely, B2 B cells have higher expression of costimulatory molecules and may provide the proinflammatory functions, such antigen presentation and cytokine production. Both of
these subsets are capable of exiting to the skin and migrating to the draining lymph
nodes, where they may also contribute to systemic immune response.

It is possible that cutaneous B-1 cells may subset into functionally distinct groups
or that waves of immigrants versus resident cells may have unique functions.
Precedence for the temporal regulation of distinct functional B cells subsets has been
described in a murine model of experimental autoimmune encephalomyelitis (244). Prior
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to disease onset, depletion of B cells leads to exacerbated disease due to the deletion of
IL-10 producing B regulatory cells.

In contrast, B cell depletion after disease onset

improves disease symptoms by reducing B-cell auto-antigen presentation to CD4 T cells
(244). Future experiments analyzing the production of IL-10 by B-1 B cells over time,
either in the CFA model from the acute to chronic phase or in cutaneous inflammation
model where IL-10 is known to play a role, will allow for a closer examination of cell type
versus temporal regulation of cutaneous B cell subsets. A more detail analysis of B1/innate B cells subsets in the skin could also elucidate their functional capacity in the
skin. Both B regulatory B10 cells and innate response activator B cells phenotypically
resemble B-1a cells (117, 206). Thus additional functional analyses will reveal other
potential innate B cell functions, such as production of GMCSF or phagocytosis.
The role of IL-10 in cutaneous disease is complex and varied. In mice
overexpressing IL-10 in the epidermis, there is reduced Langerhans cell migration to the
draining lymph node after hapten challenge along with a decreased ability to stimulate
allogeneic T cell responses (245), both of which could cause dysregulation of the
immune response in infection. However, when these mice are exposed to UVB radiation,
they develop fewer skin tumors (245), suggesting that high levels of cutaneous IL-10 can
have a protective effect.

Similarly, in a model of cutaneous Francisella tularenis

infection, IL-10-/- are more protected from lethal challenge than wildtype mice (246).
The role of IL-10 in cutaneous human autoimmune disorders is equally unclear.
In some disorders, such as systemic lupus erythematosus and bullous pemphigoid
disease, systemic IL-10 levels are elevated compared to healthy individuals (247, 248).
Conversely, in other autoimmune disorders, such as psoriasis and allergic contact
dermatitis, serum and/or local cutaneous IL-10 levels are lower than normal, and both
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diseases have been successfully treated with topical IL-10 therapy (214, 249). Although
studies of cutaneous autoimmune disorders and infections have not considered the role
of B-cell derived IL-10 in disease, case reports from B cell depletion provide insight into
the importance of the source of IL-10. A patient being treated for rheumatoid arthritis
received a B-cell depleting therapy and subsequently developed psoriasis (215).
Similarly, another individual completed treatment for B cell lymphoma that included B
cell depletion in conjunction with strong immunosuppressives that coincided with
remission of his psoriasis. When the treatment wore off, another round of B cell
depleting therapy was administered for treatment of the psoriasis; however, the psoriatic
lesions grew worse, suggesting it was the strong immunosuppressives rather than B cell
depletion that caused clinical symptoms of psoriasis to improve (216). In contrast, there
is a report of the successful use of B cell depletion for the treatment psoriatic arthritis
(250). Although interpretation of these cases is difficult due to the systemic effects of B
cell depletion, they support an active role of B cells in the cutaneous immune system.
Furthermore, as IL-10 is a critical mediator in psoriasis, these studies may allude to the
importance of proper regulation of IL-10 production by cutaneous B cells.
Understanding the homing receptors B-1 B cells use to migrate to the skin would
enable the specific targeting of cutaneous B-1 cell infiltration as a therapeutic
intervention. By inhibiting access of a certain cell subset to a particular tissue in a
disease state, the tissue microenvironment can be changed to improve clinical
manifestations of disease. Several drugs that target trafficking molecules primarily on T
cells have been developed, and they have been effective at improving several
autoimmune disorders (251, 252). One such drug, Natalizumab, targets α4 integrin and
can dramatically improve multiple sclerosis and Crohn’s disease, athough it also
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increases susceptibility to JC polyomavirus. Interestingly, there is also a reported case of
worsening psoriasis after treatment for multiple sclerosis with Natalizumab (253). From
these studies it is intriguing to speculate that human IL-10-producing B cells play a role
in psoriasis and that they may also use alpha-4 integrin to home to the skin.

Future Directions
Our studies demonstrating B-1 B cells in the skin of sheep, mice, and humans
present many questions. Although we show a unique dependence on α4β1 integrins for
migration into the skin, additional trafficking molecules must work in tandem to effectively
guide B-1 B cells into the skin. Even if B-1 B cells stably express high affinity integrin
and therefore do not need a chemokine trigger, at least one unknown chemokine
mediates chemotaxis into and through the tissue. According to the Immunological
Genome Project, B-1 B cells express mRNA for several chemokine receptors, including
CCR1, CCR6, CCR7, CCR9, CXCR4, and CXCR5. However, B-1 B cells do not express
CCR1 protein by flow cytometry, can home into the skin in the absence of CCR6, and do
not migrate to ligands for either receptor in an ex vivo chemotaxis assay (data not
shown). Additional studies should attempt to elucidate what chemokine-chemokine
receptor pair drives B-1 cell migration so that we may more fully understand the homing
capacity of this subset.
We show that peritoneal B-1 B cells migrate into the skin; however, like most
homing experiments, we recover a relatively small number of cells in the skin compared
to the total transferred. This may simply be the nature of trafficking experiments, but it
may also be due to a selective preference of a particular type of B-1 B cell. To try to
discern if a particular B-1 B cell subset may exhibit skin tropism, the B cell receptor
usage of skin B-1 B cells could be investigated. This would tell us if there is a particular
111	
  
	
  

enrichment of any VJD usage and may tell us how cutaneous B-1 B cells compare to
peritoneal and splenic B-1 B cells.
In addition to discerning trafficking and B cell receptor usage, the function of
cutaneous B-1 B cells should also be investigated. The production of IL-10 and
observation that some B-1 B cells can express Blimp-1 suggests that these B cells may
play a regulatory role in skin immunity, but this remains to be demonstrated.
Furthermore, although the CFA model is especially useful for studies in multiple species,
it may not be the best model to study B-1 B cell function. One particular model that could
be used is TLR-7-induced psoriasis-like disease in mice. It has been previously shown
that B-1 B cell produced IL-10 is critical for controlling inflammation in this model, but the
presence of B-1 B cells in the skin was not analyzed (254). Analysis of B-1 B cells in the
psoriatic skin, and if present, subsequent alpha-4 integrin blockade would demonstrate
the regulatory capacity of cutaneous B-1 B cells.
Our studies also revealed B-2 B cells in the uninflamed skin with a dramatic
increase in the chronically inflamed skin. These cells likely also fulfill a currently
unappreciated role in skin immunity, and investigation into how they migrate into the skin
as well as their function in the tissue would enhance our understanding of cutaneous
disease and inflammation.

Summary and concluding remarks
Innate lymphocytes are important in infection and autoimmune disorders; however, their
characterization in extralymphoid tissues is still underway. The results presented in this
thesis provide new insights into the recirculation and function of cutaneous γδ T cells and
B-1 B cells. In Chapter 1, we demonstrated that ovine γδ T cells in the uninflamed and
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inflamed skin and skin-draining lymph migrate through the skin independent of CCR7
with the capacity to make proinflammatory cytokines IL-17 and IFNγ. This is in line with
studies in other species, demonstrating a strength of the ovine cannulation model to
observe not only tissue-residing, but actively recirculating lymphocytes. In Chapter 2, we
showed that B cells are a component of the cutaneous immune system. This was a
heterogeneous population with both conventional and innate-like B cells. In chapter 3,
we followed up on our ovine studies in the mouse and determined that B-1 B cells
readily traffic to the skin in an alpha-4 integrin dependent mechanism. We furthermore
revealed the ability of cutaneous B-1 B cells to secrete IL-10. Collectively, the body of
work presented in this thesis highlights the diversity of lymphocyte subsets in the skin
and provides novel targets for the modulation of cutaneous immune responses.
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